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CHAPTER 1 INTRODUCTION 
 
1.1 HIV epidemiology 
According to the report of the Joint United Nations Program on HIV/AIDS 
(UNAIDS), about 2.6 million people became infected with AIDS in 2009 and an 
estimated 33.3 million people were living with the disease by the end of the year (1). 
Though the number of new infections and AIDS-related deaths have been steadily 
decreasing over the past few years (1), AIDS is still a serious global public health 
problem and a heavy socioeconomic burden.  
 
Figure 1.1 HIV life cycle. Adapted based on the figure produced by Pomerantz RJ and 
Horn DL (2). 
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1.2 HIV Life cycle  
The human immunodeficiency virus (HIV) infects CD4 positive T cells through the 
interaction between viral envelope glycoprotein (gp120 and gp41) and CD4 receptor as 
well as co-receptors (CCR5 or CXCR4). After the virus anchors to the CD4 positive T 
cell, the HIV virion fuses with the target cell. The nucleocapsid containing the viral 
genome, viral proteins, and reverse transcriptase are released to the cytoplasm of the 
target cell. The viral genome encodes three essential enzymes, the reverse transcriptase, 
integrase, and protease. The first viral encoded enzyme, reverse transcriptase, 
reverse-transcribes viral RNA to DNA. As reverse transcriptase degrades the RNA 
template, a complementary DNA strand is synthesized to form a double stranded duplex 
called proviral DNA. Integrase then inserts the proviral DNA into the host genome. The 
inserted proviral DNA is first transcribed into a messenger RNA and then translated into a 
polyprotein. At this step, the third viral enzyme, the HIV protease, is required to cleave 
the polyprotein into eight separate proteins and two small spacer peptides. The mature 
viral structural proteins assemble around the viral genome into new functional viruses. As 
the new viron buds from its host cell membrane, it is coated with viral envelope proteins 
and departs to begin a new infectious cycle.  
1.3 The HIV-1 genome 
The HIV genome consists of a long single stranded RNA molecule. The viral 
genome contains three main open reading frames, the group-specific antigen gene (gag), 
the polymerase gene (pol), and the envelope gene (env). The gag gene encodes the p55 
precursor polyprotein which is processed to generate the matrix protein (MA, p17), capsid 
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protein (CA, p24), nucleocapsid protein (NC, p7), spacer peptide 1 (SP1, p2), spacer 
peptide 2 (SP2, p1), and p6. The pol gene encodes three viral enzymes, which are the 
reverse transcriptase, integrase, and protease. The reading frames of gag and pol differ by 
one nucleotide. During translation, ribosomal frame-shifting produces the Gag-Pol 
polyprotein. The frequency of this frame-shifting is about 5 to 10% (3). Therefore, the 
three viral enzymes are expressed in the Gag-Pol precursor. The env gene encodes a 
precursor, gp160, which is processed by the host protease to generate the external 
glycoprotein gp120 and the transmembrane glycoprotein gp41. The Tat protein encoded 
by the transactivator gene (tat) is an essential viral regulatory factor interacting with an 
RNA element to activate transcription. Another essential regulatory factor is coded by the 
regulator of virion gene (rev), which promotes the nuclear export of the viral RNA. The 
product of virion infectivity factor gene (vif) preserves viral infectivity by inducing the 
degradation of an antiretroviral cytidine deaminase, APOBEC3G (apoplipoprotein B 
mRNA-editing, enzyme-catalytic, polypeptide-like 3G) (4). The viral protein R encoded 
by vpr gene regulates nuclear import of the HIV-1 pre-integration complex (5), arrests 
cell growth (6), and induces host cell apoptosis (7). The viral protein U gene (vpu) only 
exists in HIV-1. Its gene product induces CD4 degradation in the endoplasmic reticulum 
and enhances virion release from HIV-1-infected cells (8). The negative regulator protein 
gene (nef) encodes a multifunctional protein, which actually has a positive role in 
maintaining high viral load (9). The long terminal repeats (LTRs) are located at each end 
of the HIV-1 genome.  
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Figure 1.2 The HIV-1 genome. Open reading frames are shown as rectangles. 
1.4 The HIV-1 protease 
In the HIV life cycle, the protease is an essential element for viral maturation. The 
HIV protease is a homodimeric aspartyl protease, and each monomer is composed of 99 
amino acid residues with a catalytic aspartate at position 25. HIV-1 protease cleaves Gag 
and Gag-Pol polyprotein precursor encoded by the HIV-1 virus genome at nine 
processing sites to produce mature active proteins. The Pol polyproteins is first cleaved 
off from the Gag-Pol polyproteins and then further digested into protease, reverse 
transcriptase (p51), RNase H (p15), and integrase. The active site is not fully exposed, 
being covered by a two flexible β-hairpin flaps. The flaps need to open to allow the 
substrates to access the active site. The HIV-1 protease enzyme activity can be inhibited 
by blocking the active site of the protease. 
Asp25 Asp125
Flaps
Active site
Dimerization domain
 
Figure 1.3 Structure of HIV-1 protease. 
80s loop 80s loop 
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1.5 Anti-HIV drugs 
Since HIV was discovered in 1983 (10), 26 anti-HIV compounds were approved by 
the U.S. FDA within almost three decades. The latest HIV drug, rilpivirine from Johnson 
& Johnson Pharmaceuticals, was approved in May 2011. Anti-HIV drugs have been 
developed to target the various steps in the HIV life cycle. Based on the targeted step of 
HIV life cycle, anti-HIV drugs can be classified into five different categories: fusion 
inhibitors, entry inhibitors, transcriptase inhibitors, integrase inhibitors, and protease 
inhibitors. The cell entry inhibitors, enfuvirtide and maraviroc, block the entry of the viral 
particle into the host CD4+ lymphocytes. Enfuvirtide interacts with the glycoprotein gp41 
on the viral membrane to prevent the fusion of the viral particle and the host cell 
membrane (11). Maraviroc is an antagonist of the CCR5 co-receptor, which only acts on 
the macrophage-tropic (R5) HIV-1 strains (12). The inhibition of reverse transcriptase 
stops the production of proviral DNA. There are two classes of reverse transcriptase 
inhibitors, (i) Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (NRTI) and (ii) 
Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI). In the case of NRTIs, both 
nucleotide analog reverse-transcriptase inhibitors, such as tenofovir and adefovir, and 
nucleoside analog reverse-transcriptase inhibitors, such as zidovudine (AZT), didanosine 
(ddI), zalcitabine (ddC), stavudine (d4T), lamivudine (3TC), abacavir (ABC), 
emtricitabine (FTC), entecavir (INN), and apricitabine (ATC), get incorporated into the 
elongating DNA copy of HIV viral genome and cause premature termination of reverse 
transcription. The NNRTIs, such as efavirenz, nevirapine, delavirdine, etravirine, and 
rilpivirine bind to pockets other than the active site of reverse transcriptase and cause an 
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allosteric effect that inhibits reverse transcription. Integrase inhibitors are the newest class 
of antiretroviral agents. Raltegravir is the first integrase inhibitor approved by the U.S. 
FDA. Elvitegravir is undergoing Phase 3 clinical trials. Both compounds inhibit the strand 
transfer activity of integrase and halt the process of viral DNA integration (13, 14). The 
proteolytic cleavage of the polyprotein precursor is also a critical step for viral maturation. 
The inhibition of HIV protease effectively blocks the viral life cycle. The HIV-1 protease 
and its inhibitors are introduced in the following sections. 
1.6 Current HIV-1 protease inhibitors 
Based on the 2010 global report from UNAIDS, there are more than five million 
people receiving antiretroviral therapy, and this number is 13-fold higher than the number 
for 2004 (1). The combination therapy of HIV-1 protease inhibitors and reverse 
transcriptase inhibitors referred to as Highly Active Antiretroviral Therapy (HAART) is 
the current AIDS therapy that is most effective. The AIDS-related mortality has dropped 
sharply, and AIDS has gradually become a controllable, chronic disease. However, the 
extended length of time that patients take the medication and the error-prone replication 
of HIV genomes facilitate the evolution of drug resistant strains, which are the greatest 
obstacle in the treatment of HIV-1/AIDS patients. Only a few mutations in HIV-1 
protease are needed to confer drug resistance. There have been numerous studies 
published regarding multi-drug resistance with a focus on HIV-1 protease (15).  
The indispensable role of HIV-1 proteases in viral maturation makes it a popular 
target for drug design. The numerous structures of HIV-1 protease have facilitated the 
design of new and improved inhibitors. There are nine HIV-1 protease inhibitors 
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approved by the U.S. Food and Drug Administration (FDA); those inhibitors include: 
saquinavir, indinavir, ritonavir, nelfinavir, amprenavir, lopinavir, atazanavir, tipranavir, 
and darunavir. Unfortunately, resistance has been observed during the treatment with all 
of the approved HIV-1 protease inhibitors, and resistance cannot be overcome by 
increasing drug concentration due to the toxicity of protease inhibitors. Consequently, 
resistance has caused protease inhibitor treatment failure in a great number of patients 
(16). In the following section, the FDA-approved HIV-1 protease inhibitors are 
introduced. There are structural similarities among those inhibitors, and they share a 
similar binding pattern that might be the cause of the cross resistance characteristic of 
HIV-1 protease inhibitors. 
           
 
         
 
      
 
 
Figure 1.4 Chemical structures of the HIV-1 protease inhibitors approved by the US 
Food and Drug Administration. 
 
   lopinavir                  atazanavir                saquinavir  
 
tipranavir                  darunavir                 amprenavir  
indinavir                   ritonavir                 nelfinavir 
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1.6.1 Saquinavir 
Saquinavir (brand name: Invirase), the first FDA-approved HIV-1 protease inhibitor, 
was invented by Hoffmann-La Roche Inc. The original design for the precursor of 
saquinavir comprised a proline at the P1’ site and a phenylalanine at the P1 site. The 
rationale is that HIV-1 protease cleaves the substrate between a phenylalanine and a 
proline while mammalian proteases do not cleave substrates containing proline at the P1’ 
site. In the final structure of saquinavir, the proline was replaced by a 
(S,S,S)-decahydro-isoquinoline- 3-carbonyl (DIQ) group to enhance the inhibitory 
potency (Figure 1.2). The carbonyl of the DIQ group contacts the bridging water 
molecule that interacts with the inhibitor and the flaps of HIV-1 protease (17). 
1.6.2 Ritonavir 
Ritonavir (brand name: Norvir), invented by Abbott Laboratories, was originally 
designed as an HIV-1 protease inhibitor, but it was found later that ritonavir boosts the 
circulating concentration of other HIV-1 protease inhibitors by inhibiting the cytochrome 
P450 (18). Due to this function of ritonavir, it is still used with the second generation of 
HIV-1 protease inhibitors. Boosted HIV-1 protease inhibitors elevate the drug resistance 
barrier. With the isopropyl thiazolyl P3 group, ritonavir is longer than other 
FDA-approved HIV-1 protease inhibitors (Figure 1.2).  
1.6.3 Lopinavir 
Lopinavir (brand name: Kaletra, containing lopinavir and ritonavir), from Abbott 
Laboratories, was developed on the basis of ritonavir. The core region of lopinavir, a 
hydroxyethylene dipeptide isostere, is the same as that of ritonavir (Figure 1.2). The P2 
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and P2’ group are altered in lopinavir relative to ritonavir. The 5-thiazolyl P2 group of 
ritonavir is changed to a phenoxyacetyl group, and the 2-isopropylthiazolyl P2’ group of 
ritonavir is replaced by a six-member cyclic urea. In general, the new P2 and P2’ groups 
are smaller, which is designed to decrease the contact with highly variable residues at the 
82 site of HIV-1 protease (19). The substitution of the P2 and P2’ groups improves the 
inhibitory potency of lopinavir against the drug-resistant variants of HIV-1 protease (19).  
1.6.4 Indinavir 
Indinavir (brand name: Crixivan) was developed by Merck & Co., Inc. An advantage 
of indinavir is that it effectively inhibits both HIV-1 and HIV-2 while the disadvantage is 
that the circulating indinavir concentration decreases quickly. The low plasma 
concentration of indinavir usually leads to treatment failures (20). In addition, indinavir 
has a low sulibility that may result in the patients developing kidney stones. For this 
reason, indinavir has been replaced by second generation protease inhibitors. 
1.6.5 Nelfinavir 
Nelfinavir (brand name: Viracept) was made by Agouron Pharmaceuticals. One end 
of the nelfinavir molecule has the same DIQ group as saquinavir (Figure 1.2). The other 
end of nelfinavir contains a 2-methyl-3-hydroxybenzamide group. Another novel aspect 
of the nelfinavir design is that the S-phenyl group at the P1 site magnifies the potency of 
this inhibitor.  
1.6.6 Amprenavir 
Amprenavir (brand name: Agenerase), developed by Vertex Pharmaceuticals, has a 
  
10 
benzyl group at the P1 site and an isobutyl group at the P1’ site (Figure 1.2). The P1’ 
group and the phenyl amide P2’ group are connected by a sulfonamide. The asymmetry of 
the P1 and P1’ groups may favor the internal pseudosymmetry of HIV-1 protease. 
Amprenavir contains fewer chiral centers than previous HIV-1 protease inhibitors. This 
improvement simplifies the chemical synthesis and increases the oral availability (21). 
1.6.7 Tipranavir 
Tipranavir (brand name: Aptivus) is the only non-peptidomimetic HIV-1 protease 
inhibitor, which received approval from the FDA in 2005. Due to dissimilarities with 
other HIV-1 protease inhibitors, tipranavir encounters a relatively different HIV-1 
protease resistance profile (22, 23). An innovation in the tipranavir design is the 
functional substitution of the bridging water molecule connecting the inhibitor and 
protease flaps. The lactone oxygen atom of the dihydropyrone ring of tipranavir interacts 
directly with the Ile 50 residues in the flap region of the HIV-1 protease. The direct 
interaction stabilizes the protease-inhibitor complex. Though the structure of tipranavir is 
different from previous inhibitors, its contact residues of HIV-1 protease share many 
similarities with other HIV-1 protease inhibitors. Furthermore, the adverse effects of 
tipranavir are considerable, with one of the worst being hemorrhage (24). 
1.6.8 Atazanavir 
Atazanavir (brand name: Reyataz), approved in 2003, is an aza-dipeptide analogue, 
which exhibits potent anti-HIV activity. The 50% effective concentration (EC50) of 
atazanavir in cell culture is 2.6 to 5.3 nM (25). A unique character of atazanavir is the 
presence of a large phenylpyridyl P1 group that is asymmetric relative to its benzyl P1’ 
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group. 
1.6.9 Darunavir 
Darunavir, approved in 2006, is the latest HIV-1 protease inhibitor on the market. 
The hydrogen bonds that darunavir forms with the backbone of the HIV-1 protease slow 
down the development of drug resistance (26). The structure of darunavir is very similar 
to that of amprenavir. The only difference is that the P2 group of darunavir is a 
double-ringed bis-tetrahydrofuran that replaces the single-ringed tetrahydrofuran of 
amprenavir. This change allows darunavir to have more hydrogen bonds with the Asp 29 
residues of HIV-1 protease (27). Darunavir or atazanavir coadministrated with ritonavir is 
a current first-line antiretroviral regimen (28). 
1.6.10 The common mechanism of inhibitor binding 
Most current HIV-1 protease inhibitors were designed to mimic the substrate 
transition state. The hydroxyl group of the inhibitor interacts with the carboxyl group of 
the active site residues, Asp 25 and Asp 25´, by hydrogen bonds. Moreover, the 
inhibitor-contacting residues of HIV-1 protease are relatively conserved, such as Gly 27, 
Asp 29, Asp 30, and Gly 48. Despite the fact that diverse chemical groups have been 
incorporated in HIV-1 protease inhibitors, the conserved contact profile of the chemical 
groups still makes the protease inhibitors vulnerable to prevent drug resistance.  
Most inhibitor development efforts are to modify the available HIV-1 protease 
inhibitors, which inevitably causes the new inhibitors to inherit structural similarity with 
previous inhibitors. There have been many attempts to further modify current inhibitors; 
some have succeeded, while others have not shown significant benefits. A series of 
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compounds has been tested to optimize the P1 group of lopinavir, but none of them has 
shown significant benefits over the original lopinavir (29). The successful examples of 
modified inhibitors are darunavir and lopinavir, which were modified compounds of 
amprenavir and ritonavir, respectively.  
1.6.11 New design approaches for HIV-1 protease inhibitors 
Resistance has been observed with all the current HIV-1 protease inhibitors due to 
their structural similarities. Therefore, novel scaffolds of HIV-1 protease inhibitors are 
considered to be the key to overcoming drug resistance. With the combination therapy of 
structurally diverse HIV-1 protease inhibitors, HIV-1 protease is less likely to develop 
resistance to the inhibitors in the combination group. 
Designing inhibitors based on the substrate envelope of HIV-1 protease is a recent 
strategy to develop HIV-1 protease inhibitors. A substrate envelope is the overlapping 
volume occupied by multiple substrates. Based on this theory, a substrate-based HIV-1 
protease inhibitor, RO1, has been designed and synthesized (30). The results 
demonstrated that RO1 has 5 to 10 fold higher inhibitory efficacy than current HIV-1 
protease inhibitors (30). Among the current FDA-approved HIV-1 protease inhibitors, 
only tipranavir forms hydrogen bonds with the flap residues of the protease. Inhibitor 
RO1 forms more hydrogen bonds with HIV-1 protease, which enhances the binding 
energy and is also a step towards the diversity of binding patterns. However, the contact 
residues of RO1 are still the old pattern, and no novel contact has been established. The 
difficulty of complete alteration of the binding pattern might be due to the inhibitor 
design concept of substrate mimics. To develop new scaffolds of HIV-1 protease 
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inhibitors, it is necessary to adopt drug discovery strategies other than substrate mimics. 
New scaffolds of HIV-1 protease inhibitors might be the key to overcoming drug 
resistance. It is very risky to explore new structures of inhibitors. One reason is that the 
new scaffolds are less likely to be superior to the well-established old scaffolds. 
Mozenavir’s structure is highly dissimilar from other HIV-1 protease inhibitors, which 
was developed based on the cyclic urea scaffold (31). However, the clinical studies 
showed that mozenavir did not show significant advantages compared to other protease 
inhibitors on the market, and Gilead Sciences, Inc. stopped the development of mozenavir 
(32). The other reason is that new scaffolds with fewer study backgrounds may cause 
severe adverse effects. The relatively different structure of tipranavir may be not only the 
reason for generating altered drug-resistance profiles, but it is also the cause of the 
unpredictable side effects, such as hemorrhage. Based on the above summary, the 
non-peptidomimetic HIV-1 protease inhibitors seem to have a higher tendency to cause 
adverse effects. 
The discovery of new HIV-1 protease scaffolds may rely on high-throughput 
screening techniques. By screening large chemical libraries with diverse compound 
structures, the leads of new HIV protease inhibitor scaffolds could be found. After 
extensive modifications and tests, the leads of new scaffolds might become the next 
generation of HIV-1 protease inhibitors possessing novel chemical structures and 
alternative binding patterns to HIV-1 protease. A set of HIV-1 protease inhibitors that bind 
and function by various mechanisms can greatly decrease the probability for the protease 
to simultaneously develop resistance to all inhibitors. 
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1.7 Protein-ligand interactions 
The flexibility of the protein is important in the affinity and specificity of ligand 
binding as well as product release. Optimal interactions between the enzyme and the 
substrate are formed through induced conformational changes (33). The major 
interactions between the protein and the ligand are electrostatic interactions, hydrogen 
bonding, hydrophobic interactions, and van der Waals interactions. An electrostatic 
interaction is formed when oppositely charged groups interact at a distance less than 4 Å. 
(34). The charged state of some amino acid residues determines the local electrostatic 
potential of the protein, which is an important component of molecular recognition. The 
hydrogen bonds are interactions between a partially electronegative atom and a hydrogen 
atom covalently bound with another partially electronegative atom. Both the main chain 
of a protein and the side chain of polar amino acid residues can serve as hydrogen bond 
donors and acceptors. In contrast with hydrophilic interactions, such as electrostatic 
interaction and hydrogen bonding, which are usually on the surface of a protein, 
hydrophobic interactions assemble the core of a protein during folding. Van der Waals 
interactions represent attractive or repulsive force between proximate atoms. Despite the 
fact that van der Waals interactions are weak, the considerable number of van der Waals 
interactions determines the important role of this interaction in macromolecules, such as 
protein folding, protein-protein interactions, and protein-ligand interactions.  
1.7.1 Substrate binding to the HIV-1 protease 
Understanding substrate binding is an important step in drug design. Based on the 
MA/CA substrate cleavage site (Ser-Gln-Asn-Tyr-Pro-Ile-Val), the P1’ Pro substitution 
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with 20 different residues has been tested to identify the preferred P1’ residues of HIV-1 
protease, and hydrophobic residues, such as Leu, Ile, Val, Phe, and Tyr, are favorable at 
the P1’ site (35).  
The substrate envelope represents the conserved volume occupied by the nine HIV-1 
protease substrates. Designing inhibitors that fit into the overlapping volume of substrates 
can avoid the contacts with mutation hotspots of the protease (36). Based on this theory, 
the inhibitors designed to fit inside the consensus volume defined by the substrates 
exhibited potent inhibition against HIV-1 protease and low levels of resistance to a panel 
of drug-resistant HIV-1 protease variants (37).  
The most widely accepted mechanism for the hydrolysis of HIV-1 protease 
substrates is the general acid and base mechanism (38) (Figure 1.3). In the active site of 
the HIV-1 protease, one aspartate residue is protonated while the other aspartate residue is 
deprotonated (39). During cleavage, the protonated aspartate residue transfers the 
hydrogen atom to the scissile carbonyl oxygen (40). A water molecule in the active site 
attacks the carbonyl group of the scissile peptide bond of the substrate and the cleavage 
site of the substrate forms a tetrahedral oxyanion intermediate (41).  
  
16 
 
Figure 1.5 HIV-1 protease substrate cleavage mechanism. 
The Gly-rich flaps of HIV-1 protease alter the conformation from an “open” form to 
a “closed” form after ligand binding. NMR studies have demonstrated the flexibility of 
the flap region of the HIV-1 protease (42). The flexibility of the flaps is considered to be 
essential for substrate binding and product release. After the substrate is incorporated into 
the protease actives site, substrate binding stabilizes the interactions between the flaps of 
HIV-1 protease. A water molecule bridges the flap residue Ile50 and Ile50’ with hydrogen 
bonds, and this water molecule is not involved in catalysis (40).  
1.8 Summary of the HIV-1 protease structures in the dissertation 
The HIV protease structures mentioned in the dissertation are listed in the following 
table. The residues involved in crystal packing were identified using PDBePISA (Protein 
Interfaces, Surfaces and Assemblies) server.  
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Table 1.1 Summary of the HIV-1 protease structures 
PDB 
code 
Description 
Space 
Group 
Unit cell Residues involved in crystal 
packing Length (Å) Angle (°) 
2HB4 
Apo WT HIV-1 protease isolate 
NL4-3 
P 41212 
a=48.99 b=48.99 
c=105.62 
α=90 β=90 
γ=90 
4, 6-7, 35, 37, 41-42, 44, 46, 49-57, 
61, 63, 71-73, 77-79, 81, 88, 91-94  
2HB2 
Apo MDR HIV-1 protease variants 
with mutations 24I, 46I, 53L, 63P, 
77I, and 82A 
P 41212 
a=49.67 b=49.67 
c=109.61 
α=90 β=90 
γ=90 
4, 6-7, 35, 42, 50-57, 61, 71-73, 
77-79, 81, 88, 91-94 
1HHP 
Apo WT HIV-1 protease isolate 
BRU 
P 41212 
a=50.2 b=50.2 
c=106.8 
α=90 β=90 
γ=90 
4, 6-7, 35, 37, 42, 49-57, 61, 63, 
71-73, 77-79, 81, 88, 91-94 
2PC0 
Apo WT HIV-1 protease isolate 
BH10 
P 41212 
a=46.42 b=46.42 
c=101.37 
α=90 β=90 
γ=90 
4, 6-7, 39-41, 46, 48-55, 60-61, 63, 
71-74, 79, 81, 88, 91-94  
1TW7 
Apo MDR HIV-1 protease 769 
with mutations 10I, 36V, 46L, 54V, 
62V, 63P, 71V, 82A, 84V, and 90M 
P 41 
a=45.04 b=45.04 
c=105.74 
α=90 β=90 
γ=90 
4, 6-7, 34, 37-44, 48-61, 63, 71-74, 
77-81, 88, 91-94 
2Q5K 
WT HIV-1 protease in complex 
with lopinavir 
P 212121 
a=51.34 b=58.04 
c=61.13 
α=90 β=90 
γ=90 
1-4, 6-7, 12-19, 34-46, 48-53, 
54-55, 57-58, 59, 61-63, 65, 67-72, 
77-81, 88, 91-94, 96, 98-99 
2O4P 
WT HIV-1 protease in complex 
with tipranavir 
P 21212 
a=58.61 b=86.26 
c=45.89 
α=90 β=90 
γ=90 
1-2, 4, 6-7, 12, 14, 17-21, 34-46, 
48-49, 51-53, 55, 57-58, 61, 63, 65, 
67-68, 70-73, 79-83, 88, 91-92, 94, 
99 
3SPK 
MDR HIV-1 protease 769 in 
complex with tipranavir 
P 61 
a=63.12 b=63.12 
c=83.54 
α=90 β=90 
γ=120 
1-4, 6-8, 10, 12-14, 16-21, 34-35, 
37-41, 43-48, 51-53, 58, 65, 67-68, 
74, 79-81, 94, 96, 98 
3BVB 
WT HIV-1 protease in complex 
with darunavir 
P 21212 
a=58.26 b=85.91 
c=46.05 
α=90 β=90 
γ=90 
2, 4, 6-7, 12, 14, 17-20, 34-37, 
40-46, 48-53, 55, 57-58, 61, 63, 65, 
67-68, 70-73, 79-83, 88, 91-92, 94, 
96 
3SO9 
MDR HIV-1 protease 769 in 
complex with darunavir 
P 212121 
a=28.9 b=66.38 
c=90.84 
α=90 β=90 
γ=90 
1-2, 4, 6, 14-18, 21, 34-46, 48-58, 
60-65, 70, 72, 77-82, 87, 92-94, 96, 
98-99 
1A8K 
WT HIV-1 protease in complex 
with CA/p2 P1’F peptide 
P 1121 
a=59.6 b=52.2 
c=61.7 
α=90 β=90 
γ=90 
2, 4, 6, 10-12, 14, 19, 21, 34-35, 
41-46, 52-55, 57, 63, 65, 67-68, 
70-72, 79-81, 92 
N/A 
MDR HIV-1 protease 769 in 
complex with CA/p2 P1’F peptide 
P 212121 
a=28.77 b=65.39 
c=92.82 
α=90 β=90 
γ=90 
1-2, 4, 6, 14-19, 21, 29, 34-37, 
39-46, 49-58, 60-61, 63-65, 67-68, 
70-72, 77-82, 87, 91-94, 96, 98-99 
1KJ7 
WT HIV-1 protease in complex 
with p2/NC peptide 
P 212121 
a=51.51 b=59.43 
c=61.74 
α=90 β=90 
γ=90 
1-4, 6-7, 12-14, 17, 19, 34-35, 37, 
41-46, 48-55, 61, 63, 65, 67-72, 
77-81, 88, 91-94, 96 
N/A 
MDR HIV-1 protease 769 in 
complex with p2/NC peptide 
P 212121 
a=28.62 b=63.85 
c=91.11 
α=90 β=90 
γ=90 
1-2, 4, 6, 14-17, 19, 21, 34-44, 
46-58, 59-61, 63-65,  67-72, 74, 
77-82, 87, 91-94, 96, 98-99  
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1.9 Hepatitis C virus and treatment 
The hepatitis C virus (HCV), a member of the Flaviviridae family, is a 
single-stranded positive sense RNA virus. It is the major risk factor for liver cirrhosis and 
hepatocellular caricinoma and the virus infects approximately 170 million people 
worldwide, four million of which are in the United States (43, 44). The classic treatment 
for HCV infection is a combination of pegylated interferon and ribavirin. Both antiviral 
drugs function indirectly since neither of them targets a specific HCV protein or RNA. 
The pegylated interferon and ribavirin combination treatment requires a weekly injection 
for 24 or 48 weeks, yet only less than 50% patients achieve a sustained virological 
response. Furthermore, there are a number of serious adverse effects associated with 
interferon treatment, such as leucopenia, thrombocytopenia, neutropenia, depression, 
fatigue, and "flu-like" symptoms, that makes withstanding the long treatment period 
difficult for patients (45). Consequently, there is a need for safer and more effective drugs 
for the treatment of HCV. 
1.10 HCV life cycle  
The HCV infection starts with the virus binding to the cell surface receptor. Several 
putative receptor molecules have been proposed, such as the cluster of differentiation 81 
(CD81) (46), scavenger receptor B type I (SR-BI) (47), dendritic cell-specific 
intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN or CD209) (48), 
liver/lymph node-specific intercellular adhesion molecule-3 (ICAM-3)-grabbing integrin 
(L-SIGN or CD209L) (49), low-density lipoprotein receptor (LDL-R) (50), and 
asialoglycoprotein receptor (ASGP-R) (51). Due to the narrow host specificity, HCV only 
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infects humans and chimpanzees. Genetically humanized mice expressing human CD81 
and occludin are able to establish HCV infection (52). L-SIGN molecules abundantly 
expressed on liver sinusoidal endothelial cells play a crucial role in HCV tissue tropism 
(49).  
 
Figure 1.6 HCV life cycle. Adapted from the figure produced by Moradpour D, et al (53) 
After attaching to a host receptor, the viral surface glycoproteins trigger 
receptor-mediated endocytosis. By uncoating the capsid shell of the virion, 
positive-strand genomic RNAs are released from the virus, and the RNAs are attached to 
the endoplasmic reticulum. A complementary negative-strand RNA is synthesized based 
on the viral RNA. The negative-strand RNA is then utilized as a template to produce 
thousands of positive-strand viral RNA copies by the viral polymerase NS5B. The 
positive-strand RNA is used for polyprotein translation. The internal ribosome entry site 
(IRES) of HCV RNA regulates the assembly of translation initiation complexes by 
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recruiting both cellular proteins and viral proteins (54). Then, a large precursor 
polyprotein with approximately 3,000 amino acid residues is synthesized using the viral 
genomic RNA. A total of ten proteins are produced by the cleavage of the polyprotein. 
The structural proteins are released by host enzymes while the non-structural proteins are 
cleaved off by the viral enzyme. The zinc-dependent NS2-3 autoprotease liberates the NS3 
by self-cleavage. The efficient NS2-3 proteinase activity requires the last 130 residues of 
NS2 and the first 180 amino acids of NS3 (55). The NS3 assembles with its cofactor 
NS4A and performs self-cleavage at the NS3-NS4A junction to liberate NS4A. The 
NS4A-NS4B, NS4B-NS5A, and NS5A-NS5B junctions are cleaved by NS3/4A protease 
(56). A host peptidase cleaves the E1-E2 junction. The envelope proteins, E1 and E2, 
form a heterodimer after N-glycosylation (57). 
The core proteins are self-assembled and bind the viral RNA to generate the 
nucleocapsid. The glycoproteins E1 and E2 associated with the double lipid layers form 
an envelope to cover the nucleocapsid. The newly formed viral particles are secreted from 
the host cell to initiate a new infectious cycle.  
 
 
Figure 1.7 The HCV genome. Adapted from the figure produced by Tan SL, et al.(58) 
1.11 The HCV protease 
The HCV protease emerges as a desirable drug target, because it is essential for viral 
maturation. The single polyprotein encoded by the HCV genome is proteolytically 
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processed by the HCV NS3/4A serine protease which is responsible for the cleavage at 
four junctions of the HCV polyprotein including NS3/4A (self-cleavage), NS4A/4B, 
NS4B/5A, and NS5A/5B (59-61).  
The extensive functional studies of NS3/4A protease and the solved crystal structures 
have improved our understanding of this protease. NS3 is a bifunctional enzyme; the 
protease domain is located at the N-terminus and a helicase domain at the C-terminus. 
The protease and helicase domains function independently (62, 63). NS4A, a 54-residue 
peptide, is required as a co-factor to increase the activity of the NS3 protease (64, 65); 
this may be due to the incorporation of NS4A into the β sheet at the N-terminus of the 
NS3 protease with tight non-covalent bonds (66). Another possible function of NS4A is to 
anchor NS3 to the membrane (67). 
       
telaprevir          boceprevir 
Figure 1.8 Chemical structures of HCV protease inhibitors. 
1.12 The HCV protease inhibitor, telaprevir 
Currently, two HCV protease inhibitors have been approved by the US FDA, 
telaprevir (VX-950) and boceprevir. Telaprevir is an oral drug approved in May 2011 
which is a potent inhibitor of the genotype 1 HCV protease. Telaprevir was developed by 
Vertex Pharmaceuticals as a peptidomimetic inhibitor, which is derived from the 
N-terminal product of the NS4B/5A. Telaprevir inhibits the NS3/4A protease by binding 
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to the active site with its α-ketoamide moiety. The crystal structure of the NS3 protease 
with the NS4A peptide or NS3/4A fusion from HCV genotypes 1a and 1b have been 
solved (66, 68). The shallow substrate-binding groove of the protease increases the 
difficulty of inhibitor binding, but α-ketoamide inhibitors exhibited an unusual binding 
mechanism in the catalytic site of the protease. By optimization of α-ketoamide as a 
serine trap group to covalently anchor inhibitors and to increase their affinity to the 
protease, telaprevir, a potent, covalent, reversible, and selective inhibitor of HCV NS3/4A 
protease, was developed (69). The covalent bond between telaprevir and the protease is 
hydrolysable, which makes telaprevir a reversible inhibitor. 
After a treatment with telaprevir for 2 to 3 days, the viral load in patients with 
genotype 1 chronic hepatitis C was reduced by hundred to thousand folds (70). At the end 
of a 14-day treatment with Telaprevir, up to a 10,000-fold reduction in HCV viral load 
was observed, while in some patients the virus became undetectable (70). Telaprevir 
dramatically shortened the duration of therapy, and fewer adverse effects were noted (70, 
71). Therefore, with such a drug, the efficacy and tolerability of HCV treatment could be 
greatly enhanced. Furthermore, telaprevir cured the genotype 1 hepatitis C patients who 
had failed to achieve a sustained virological response with interferon-based therapy. 
At least six major HCV genotypes have been identified with varied geographic 
distributions. Each genotype is further divided into subtypes. Genotype 1a HCV is 
prevalent in North and South America; genotype 1b, in Europe and Asia; genotype 3, in 
Australia and South Asia; genotype 4, in Egypt, France and Central Africa. Genotype 2 
exists in Japan, China, the United States, and Europe. Genotype 5 is observed in South 
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Africa and Saudi Arabia. Genotype 6 is restricted to Hong Kong, Macau, and Vietnam.  
The various HCV genotypes respond differently to treatments. For example, patients 
infected with genotype 2 HCV showed better response to the interferon therapy relative to 
the other genotypes (72). Although telaprevir has demonstrated strong antiviral activity in 
patients with chronic genotype 1 HCV infection in the clinical trial, its efficacies with the 
HCV genotypes 4, 5, and 6 have not been fully investigated. The sequence similarities 
between NS3 protease of genotype 1 and NS3 protease of genotype 4, 5, and 6 vary 
approximately 60% to 80%. Due to the relatively low sequence similarity between the 
HCV genotype 1 protease and proteases from other HCV genotypes, the inhibitory 
efficacies of non-genotype 1 proteases is likely affected. Enzyme assays demonstrate that 
the potency of telaprevir against the HCV NS3/4A proteases of genotype 2 is similar as 
that of telaprevir against the genotype 1 HCV proteases, but telaprevir exhibited reduced 
activity against the genotype 3 HCV proteases (73). Interestingly, the protein sequence 
similarities between the genotype 1 and genotype 2 proteases are less similar compared to 
the protease sequences between genotypes 1 and 3. Therefore, structural information is 
critical to explain the varied potency of telaprevir against non-genotype 1 HCV proteases. 
A previous study showed the mutations V36A/G/L/M and T54A/S in NS3/4A protease 
from HCV genotype 1 strain were associated with low to medium levels of telaprevir 
resistance (74). The mutation V36L exists in genotype 4a, 4d, 5a, and 6f HCV protease 
sequences. Thus, the comparison of telaprevir binding between the HCV genotype 1 
protease and proteases from other genotypes will provide an insight of how to modify the 
inhibitor to restore the enzyme inhibition. 
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CHAPTER 2 METHODS 
 
2.1 Synthesis of lopinavir analog 
 The synthesis of the lopinavir analog (Figure 2.1) was modified from the lopinavir 
synthesis developed by Abbott Laboratories (75). The amount of reagents described in the 
following sections was optimized for lopinavir analog synthesis. 
                            
 
                         
                                                 
 
 
Figure 2.1 Synthetic scheme for the lopinavir analog. 
 
2.1.1 Synthesis of (L)-N,N-dibenzylphenylalanine benzyl ester (compound 2) 
In a round flask, 15 g L-phenylalanine (compound 1) and 49.8 g K2CO3 were 
dissolved in water, and 44 ml benzyl bromide was then added to the aqueous solution. 
The solution in the flask was boiled overnight. The reaction was stopped by cooling down 
the flask to room temperature. Ethyl acetate and water were used to extract the organic 
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phase from the product mixture. The benzyl ester in the organic phase was further washed 
with saturated sodium chloride solution. The organic phase was dried in vacuo to yield a 
thick yellow oil. The product was purified by a silica gel column chromatography (ethyl 
acetate:n-hexane = 1:4 v/v) to yield 7.1 g benzyl ester (compound 2, 18% yield).  
2.1.2 Synthesis of (4S)-4-dibenzylamino-3-oxo-5-phenyl-pentanonitrile (compound 3) 
7.1 g benzyl ester dissolved in 19 ml anhydrous tetrahydrofuran (THF) was cooled to 
-45°C with an acetone solution mixed with dry ice. 4.26 g sodium amide was dissolved in 
47 ml anhydrous THF in a separate flask and cooled to -45 °C. The air in both sealed 
flasks was replaced by nitrogen. 6.14 ml acetonitrile was added to the sodium amide 
solution and reacted for 30 min to generate an anion solution. The cold anion solution was 
transferred to the benzyl ester solution by syringe. The mixture was stirred at -45 °C for 7 
hr. The progress of the reaction was monitored by sampling and examination using thin 
layer chromatography (TLC). The Rf is 0.55 (ethyl acetate:n-hexane = 1:3 v/v). The 
reaction was quenched with 50 ml 25% (w/v) aqueous citric acid. The organic phase was 
extracted, washed with saturated sodium chloride solution, and dried with magnesium 
sulfate. The crude product was dissolved in boiling ethanol. As the solution was cooled 
down resulting in 4.5 g white product (74% yield per reaction).  
2.1.3 Grignard reaction  
3.8 g of magnesium turnings were cut and weighted in a dry two-funnel flask that 
was connected to a condensation tower. The reaction system was dried thoroughly by 
heating and filled with argon. After cooling the reaction system with ice, 17.7 ml of 
1-chloro-2-methyl propane was added to the flask. Iodine powder (10 mg) and a few 
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drops of 1,2-dibromoethane were added to the solution mixture as an activating agent. 
The reaction was stirred at room temperature for 30 min. The boiling of this solution 
indicated the generation of the Grignard reagent, isobutyl magnesium chloride. In a 
separate flask, 4.5 g of compound 3 was dissolved with anhydrous THF and transferred to 
the flask containing Grignard reagent. The reaction mixture was stirred over night at room 
temperature. The reaction was stopped by addition of 10% (w/v) citric acid. The product 
in the organic phase was extracted and purified by silica gel column chromatography with 
(ethyl acetate:n-hexane = 1:20 v/v, Rf 0.39), which yielded 2.5 g of enaminone 
(compound 4, 47% yield).   
2.1.4 Reduction reaction  
A two-step reduction reaction generated the largest percentage of desired enantiomer. 
1 g sodium borohydride in 54 ml anhydrous THF was cooled to 0°C before 4.3 ml 
methansulfonic acid was slowly added to the suspension. The slow addition was to ensure 
that the temperature of the suspension remained below 5°C. A solution of enaminone (2 g) 
dissolved in THF and 5 ml isopropanol was added the previous suspension. The mixture 
was stirred at 4°C for 28 hr. In the second step of reduction, 5 ml trifluoroacetic acid was 
slowly added to 2 g sodium borohydride in 26 ml THF to ensure a temperature below 
15°C. The suspension was stirred at room temperature for 4 hr. The reaction was 
quenched with 3 N sodium hydroxide. By adding tert-butyl methyl ether, the organic 
layer was separated and washed with 0.5 N sodium hydroxide, 20% (w/v) ammonium 
chloride, and 6% (w/v) sodium chloride. 
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2.1.5 Coupling of Acid-5 
In a flask filled with nitrogen gas, 0.7 g Acid-5, purchased from Biofine International 
Inc. (Vancouver, Canada), was dissolved in 9.7 ml THF and cooled to 4°C. 0.35 ml 
thionyl chloride was added dropwise to the Acid-5. The mixture was stirred for 5.5 hr 
until it became a thick slurry. The slurry was dried in vacuo, dissolved in heptane, and 
further dried to thoroughly evaporate the residual thionyl chloride. The dried product, 
acyl chloride, was dissolved in 3.45 ml dimethylformamide. 1.5 g of product 5 was added 
to 0.96 ml ethyl acetate containing 0.72 g dissolved imidazole. The solution was rapidly 
transferred to the acyl chloride and stirred for 1 hr at 0°C followed by overnight stirring at 
30°C. The reaction was quenched with an aqueous hydrochloric acid solution by 
adjusting the aqueous layer to pH 3. The aqueous layer contained unreacted Acid-5, and 
the organic layer was extracted for further clean up. The crude product was loaded on a 
silica column. The impurity was eluted with a mobile phase of 90% hexane, 10% 
isopropyl alcohol, and 0.1% ammonium hydroxide. The product was eluted with 89% 
dichloromethane, 10% methanol, and 1% ammonium hydroxide. 
2.1.6 Deprotection and Acid-3 coupling 
Two benzyl protective groups from compound 6 were removed by catalytic 
hydrogenation with palladium on carbon. The reaction was under 65~75 psi hydrogen 
pressure for two days. 0.076 ml thionyl chloride was added to 0.167 g Acid-3 (Biofine 
International Inc.,Vancouver, Canada) dissolved in 0.32 ml ethyl acetate and 0.1 ml 
dimethylformamide and stirred for 5 hr at 50°C. The activation of Acid-3 was completed 
under nitrogen atmosphere. 0.25 g deprotected compound 7 and 0.28 g sodium 
  
28 
bicarbonate were dissolved in ethyl acetate/water (1:1, v/v). The activated Acid-3 was 
transferred to the compound 7 by syringe and stirred at room temperature for 1 hr. The 
final compound 8 in the organic layer was washed with 5% (w/v) sodium bicarbonate 
solution and water sequentially. The dry final product (compound 8) was 0.2 g. The 
products of each reaction were confirmed by mass spectrometry. 
2.2 Protein expression and purification 
Table 6.1 lists the protein sequences of MDR HIV-1 proteases. Active and inactive 
MDR HIV-1 protease genes were codon optimized for E. coli expression with the 
software DNA 2.0 (76), synthesized by GENEART, Inc. (Regensburg, Germany), and 
inserted into the pET21b plasmid. The inactive MDR 769 82T protease had an active site 
mutation, D25N, to eliminate catalytic activity. To prevent auto-proteolyses, the Q7K 
mutation was introduced into the active MDR HIV-1 protease gene. All MDR HIV-1 
proteases were expressed in the E. coli strain BL21 (DE3) pLysE. E. coli cells were lysed 
by sonication. The HIV-1 protease expressed in inclusion bodies was separated by 
centrifugation and dissolved in a buffer of 50 mM Tris, 25 mM sodium chloride, 0.2% 
β-mercaptoethanol, and 6 M urea. The dissolved HIV-1 protease variants were purified 
using a Q-Sepharose ion exchange column (Amersham Biosciences, Piscataway, NJ) 
pre-equilibrated with the buffer containing 6 M urea. The optimal buffer pH varied from 
7.8-8.6 for each of the protease variants. The flow-through containing the pure HIV-1 
protease was refolded in the dialysis buffer (20 mM sodium phosphate, 0.2% 
β-mercaptoethanol, and 10% glycerol) with step-wise decreases in urea concentration. 
The final protein buffer was 20 mM sodium acetate, pH 5.0, 1 mM dithiothreitol (DTT), 
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and 10% (v/v) glycerol. The proteases prepared for crystallization were concentrated to 
1.5 mg/ml using Amicon concentrators with a 5-kDa molecular mass cut-off (Millipore 
Corporate, Billerica, MA). 
2.3 Protease inhibition assays 
HIV protease Forster Resonance Energy Transfer (FRET) substrate I, purchased 
from AnaSpec, Inc. (Fremont, CA, USA), was used in the half-maximal inhibitory 
concentration (IC50) determination experiments. The FDA-approved HIV-1 protease 
inhibitors were kindly provided by the NIH AIDS Research and Reference Reagent 
Program (www.aidsreagent.org). The CA/p2 pseudo peptide with a reduced scissile 
peptide bond [-ψ(CH2NH)-] was synthesized in the Department of Chemistry, Wayne 
State University. The fluorescence emitted by substrate cleavage was monitored by a 
microplate reader (SpectraMax M5, Molecular Devices, Sunnyvale, CA) at a 340 nm 
excitation wavelength with an emission wavelength of 490 nm. The HIV-1 protease 
reaction buffer was adjusted to pH 4.7 [0.1 M sodium acetate, 1.0 M sodium chloride, 1.0 
mM ethylenediaminetetraacetic acid (EDTA), 1.0 mM DTT, 10% dimethylsulfoxide 
(DMSO), and 1mg/ml bovine serum albumin (BSA)]. In the reaction buffer containing 5 
µM FRET substrates, the concentration of all the HIV-1 proteases used in the enzyme 
assays was adjusted to a substrate cleavage velocity of 0.08 Relative Fluorescence Units 
(RFU)/sec. The final HIV-1 protease concentration was approximately 7 nM. The 
protease inhibitor was serially diluted in DMSO from 10 µM to 0.013 nM. The protease 
variants and inhibitors were pre-incubated at 37°C for 20 min prior to signal monitoring. 
An enzyme-free control was tested as the background substrate fluorescent signal. The 
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progress of the reaction was monitored over 20 min sampling fluorescence at 1 min 
intervals. The FRET data were plotted with the software SoftMax Pro V5.2 (Molecular 
Devices, Sunnyvale, CA) to determine the IC50 values. The difference in Gibbs free 
energy (∆∆G) was calculated from the formula ∆∆G = −RT ln[IC50(MDR)/IC50(WT)], 
where the IC50(MDR) is the IC50 value inhibiting the MDR HIV-1 protease and the 
IC50(WT) is the IC50 value inhibiting the wild-type (WT) HIV-1 protease. 
2.4 HIV-1 Protease substrate interference assays 
In the enzyme reaction buffer, a regular HIV-1 protease substrate, a heptapeptide, 
was mixed with the FRET HIV-1 protease substrate (AnaSpec Inc., Fremont, CA) to 
reach a final concentration of 100 µM regular substrate and 2.5 µM FRET substrate. The 
nine substrate hepta-peptides were purchase from SynBioSci Corporation, Livermore, CA 
(Table 6.2). All the hepta-peptides were purified by HPLC to a purity higher than 98%. 
The procedure of substrate interference assay was similar to the protease inhibition assay 
except that the inhibitor was replaced by a regular peptide substrate. The HIV-1 protease 
reaction buffer was 0.1 M sodium acetate, 1.0 M sodium chloride, 1.0 mM 
ethylenediaminetetraacetic acid (EDTA), 1.0 mM DTT, 10% dimethylsulfoxide (DMSO), 
and 1mg/ml bovine serum albumin (BSA) at pH 4.7. Upon the addition of the HIV-1 
protease, the fluorescent signal emitted through the cleavage of the FRET substrate was 
recorded using a SpectraMax M5 instrument (Molecular Devices, Sunnyvale, CA, USA) 
at an excitation wavelength of 340 nm and an emission wavelength of 490 nm. The 
protease concentration was adjusted to a substrate cleavage velocity of 0.08 RFU/sec in 
the absence of regular (non-fluorescent) substrate. In the enzyme reaction buffer, a regular 
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HIV-1 protease substrate was mixed with the FRET HIV-1 protease substrate to reach a 
final concentration of 100 µM and 2.5 µM, respectively. The average velocity of FRET 
substrate cleavage in RFU/min was calculated based on fluorescent signals at 30 time 
points over 30 min. In the control experiment, the average velocity of FRET substrate 
cleavage was determined in the absence of regular substrate. The result was illustrated by 
a bar chart representing the ratio of the average FRET substrate cleavage velocity in the 
presence of a regular substrate over the average FRET substrate cleavage velocity in the 
absence of a regular substrate. 
2.5 Crystallization and diffraction data collection 
Inhibitors (tipranavir and darunavir) and substrates (p2/NC and CA/p2) were 
co-crystallized with the MDR769 82T inactive protease using the hanging drop vapor 
diffusion method. The expression levels of the active MDR protease variants were 
generally lower than the expression levels of the inactive enzymes, and the protein 
amount of the active MDR protease variants was insufficient for crystallization 
experiments. The protease and ligand were pre-mixed at a molar ratio of 1:20 before 
crystallization set-up. The protease-ligand solution was then mixed at 2:1 v/v ratio with 
the precipitant solution. The optimal crystallization condition was obtained from a set of 
precipitant solutions (0.1 M citric acid/MES/HEPES and 0.8~2.8 M ammonium sulfate at 
pH 4.0~6.0). The reservoir volume was 750 µl. The MDR 769 82T-p2/NC complex was 
crystallized from 0.1 M citric acid and 2.4 M ammonium sulfate at pH 5.2 while the 
MDR 769 82T-CA/p2 complex, MDR 769 82T-darunavir complex, and MDR 769 
82T-tipranavir complex were crystallized from 0.1 M MES and 2.4 M ammonium sulfate 
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at pH 6.0. The reservoir volume was 750 µl. Needle shaped crystals grew to a suitable 
size for diffraction within a week. The crystals were placed in a 30% w/v glucose 
cryoprotectant solution before they were frozen in liquid nitrogen. The diffraction data 
were collected at the Life Sciences Collaborative Access Team (LS-CAT) at the Advanced 
Photon Source (APS) Sector 21, Argonne National Laboratory (Argonne, IL, USA) and 
the diffraction data were processed with the HKL2000 program suite (77).  
2.6 Structure refinement and analysis 
Molecular replacement was performed with the CCP4 program Molrep-autoMR (78). 
A previously solved HIV-1 protease structure was used as the search model for molecular 
replacement. The models of darunavir and tipranavir were built with the program COOT 
(79) using a ligand finding algorithm where the molecular formulas of the inhibitors were 
provided in SMILES representation. The protease-ligand model was further refined using 
the program Refmac5. The tipranavir molecules were refined in two orientations with 
half-occupancy while the darunavir molecule was refined in one orientation with 
full-occupancy. Restrained anisotropic refinement was used for the tipranavir-MDR 769 
82T co-crystal structure. The structure was validated using Procheck V3.4.4 (80). The 
models of tipranavir or darunavir complexed with MDR 769 82T were analyzed for 
molecular interaction using the program LIGPLOT V4.5.3 (81). 
The co-crystal structures were deposited in the Protein Data Bank 
(http://www.pdb.org/). The accession codes for the darunavir-MDR 769 82T complex and 
the tipranavir-MDR 769 82T complex are 3SO9 and 3SPK, respectively. 
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2.7 Virtual screening and protein-compound docking studies 
The large scale screening was conducted using a fast pre-screening tool, eHiTS 
LASSO (Ligand Activity in Surface Similarity Order) 2009 (82). Compound libraries 
were downloaded from the ZINC database of commercially-available compounds 
(http://zinc.docking.org/). 
The chemical structure of compound GR346 was drawn in the program 
ChemBioDraw Ultra 12.0. The three-dimensional structure of GR346 was obtained by 
energy minimization using the GlycoBioChem PRODRG2 Server 
(http://davapc1.bioch.dundee.ac.uk/prodrg/). The electrostatic descriptor gasteiger charges 
were added to atoms of protein and ligand.  
To examine the binding of the lead compound from virtual screening, the compound 
was docked into the binding pocket of HIV-1 protease using the program AutoDock4 
(83). 
2.8 Differential scanning fluorimetry  
Differential scanning fluorimetry (DSF) was used to detect the protein melting 
temperature change after ligand binding (84). The bigger the melting temperature change, 
the tighter the ligand binding. A modified procedure is described as follows. The HIV-1 
protease was diluted in the buffer of 100 mM Sodium acetate-AcOH and 150 mM NaCl at 
pH 5.0 to reach a final concentration of 0.4 mg/ml. The protease solution was 
pre-incubated with 500 µM protease inhibitors. 5×SYPRO orange dye (stock 
concentration 5,000×, Sigma-Aldrich, Inc., Saint Louis, Missouri, USA) was added to the 
protease-inhibitor mixture. The protein-dye solution (100 µl) was heated from 25°C to 
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82°C. During the heating process, the fluorescence signal was read using a microplate 
reader (SpectraMax M5, Molecular Devices, Sunnyvale, CA) with the excitation and 
emission wavelength at 492 nM and 610 nM, respectively. 
2.9 Initial model preparation for molecular simulation 
The X-ray structures of the protease-substrate complex (MDR 769 in complex with 
the substrate p2/NC) is solved and used as an initial structure for homology modeling. 
The complexes of MDR 807-p2/NC, MDR 1385-p2/NC, MDR 3761-p2/NC, and 
NL43-p2/NC were constructed using SWISS-MODEL (85). Similarly, a series of HIV-1 
protease-CA/p2 complexes were built based on the MDR 769-CA/p2 co-crystal structure. 
Based on the catalytic mechanism of HIV-1 protease, Asp 25 was assigned as a 
protonated state while Asp 25’ was assigned as a deprotonated state. All histidine residues 
were assigned a neutral charge. Protonation states of other amino acid residues were 
assumed based on the buffer pH in the HIV-1 protease enzymatic assays (pH 4.7). To 
avoid simulating a catalytic interaction, positional restraints were applied to the scissile 
peptide bond of the substrate and the β-carboxyl groups of catalytic residue Asp 25 and 
Asp 25’. The HIV protease-substrate complex was placed into an orthogonal TIP3P water 
box. The TIP3P is a three-site (three interaction sites) water model, which is one of the 
most widely used water models. The protease complex was at least 12 Å from the edge of 
the water box. Na+ and Cl- ions were added to neutralize the simulation system. 
In the preparation of the NS3/4A HCV protease, the NS3 protease (from residue 1 to 
residue 181) and NS4A peptide (from residue 21 to residue 32) of HCV genotype 1b, 4a, 
5a, and 6a were modeled based on a structure of HCV NS3/4A protease with a ketoamide 
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inhibitor (PDB: 3KN2) using SWISS-MODEL (85). The NS4A peptide binds 
non-covalently to the NS3 protease domain. Telaprevir was built with ChemBio3D and 
manually superimposed on the ketoamide inhibitor in the crystal structure. As a common 
mechanism of ketoamide inhibitors against the HCV protease, telaprevir formed a 
covalent bond with the hydroxyl oxygen of the catalytic residue Ser 139. The topology 
and force field parameters for telaprevir were initially generated using ParamChem 
(https://www.paramchem.org/), the CHARMM General Force Field (CGenFF) program 
for automatic atom typing and assignment of parameters and charges by analogy. The 
topology file and parameter file of telaprevir were then manually edited to covalently 
attach the drug to the Ser 139. Finally, the HCV protease complexes including NS3 
protease domain, NS4A peptide, and telaprevir were solvated in a water box where the 
edge of the box is no less than 12 angstroms away from the protease complex. The system 
was neutralized with Zn2+ and Cl- ions. 
2.10 Molecular dynamics simulation 
The MD simulations were performed using the parallel computing program Scaling 
NAno Molecular Dynamics (NAMD) V. 2.7b (86). The protease complex models were 
solvated in a water box using TIP3P models for water molecules. To prevent translational 
and rotational displacement and to prevent the simulation of the catalytic reaction, 
positional restraints were applied for the carbonyl group of the substrate scissile peptide 
bond and the catalytic residue Asp 25 and Asp 25’ of the HIV-1 protease. The cutoff for 
non-bonded interactions was 10 Å. Particle Mesh Ewald was implemented; the Particle 
Mesh Ewald method calculates direct-space interactions within a finite distance using a 
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modification of Coulomb’s law, and in reciprocal space using a Fourier transform to build 
a “mesh” of charges, interpolated onto a grid (87). The systems were energy minimized 
using a conjugate gradient method and gradually heated from 70K to 310K in 200 ps. 
Simulations were conducted at 310K and 1.0 atm (NPT ensemble) for 10 ns using the 
CHARMM force field 27 and a timestep of 2 fs.   
An example of NAMD configuration commands with annotations is listed as follows. 
## Adjustable Parameters 
structure input.psf ; # Specify a protein structure file that contains molecular 
characteristics required by a particular force field.  
coordinates input.pdb ; # Specify an atomic coordinate file 
set temperature 310 ; # The simulation was conducted at 310 K. 
set outputname output ; # Name the output files 
firsttimestep 0 ; # Start the simulation from step 0. 
## Simulation Parameters 
paraTypeCharmm on ; # Turn on CHARMM force field. 
parameters Par_all27_prot_na.prm ; # Specify the CHARMM27 parameter 
file which define forces and energies for protein, lipid, DNA, and 
RNA. 
parameters par_all36_cgenff.prm ; # Specify the CHARMM General Force 
Field parameter file for compounds. 
temperature $temperature ; # Read temperature from “temperature” variable. 
reassignFreq   2000 ; # Reassign temperature every 2000 steps. 
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reassignTemp 70 ; # Increase temperature from 70 K (the liquid nitrogen 
temperature). 
reassignIncr   5 ; # The temperature increment is 5 K. 
reassignHold   310 ; # Hold the temperature at 310 K. 
# Force-Field Parameters 
exclude scaled1-4 ; # Four adjacent covalently bonded atoms are excluded from 
non-bonded calculations. 
1-4scaling 1.0 ; # The constant factor of electrostatic interactions for 1-4 atom pairs. 
cutoff  12. ; # The cutoff distance for non-bonded interaction is 12 Å. 
switching on ; # Smoothing functions are applied to both the electrostatics and van der 
Waals forces. 
switchdist 10. ; # The smoothing function takes effect when atom distance is between 
10 and 12 Å. 
pairlistdist 13.5 ; # When distance between atoms is less than 13.5 Å in each cycle, the 
atom pair is included in pair list for electrostatics and van der Waals 
interaction calculation. 
margin 2.5 ; # Add 2.5 Å extra length in patch dimension. 
# Integrator Parameters 
timestep 2.0 ; # The length of each step is 2fs. 
rigidBonds all ; # The bond between hydrogen and its bonded atoms is 
constrained. 
nonbondedFreq 1 ; # Non-bonded interactions are calculated in every time step. 
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fullElectFrequency 2 ; # Full electrostatic interactions are calculated in every 2 time 
step. 
stepspercycle 10 ; # The interacting particle lists are updated every 10 time step. 
# Constant Temperature Control 
langevin on ; # Perform Langevin dynamics to introduce additional damping 
and random forces to the system. 
langevinDamping 5 ; # Langevin damping coefficient is 5/ps 
langevinTemp $temperature ; # Langevin dynamics adjust the effect on atoms 
based on the temperature variable. 
langevinHydrogen off ; # Turn off Langevin dynamics for hydrogen atoms. 
# Constant Pressure Control 
useGroupPressure yes ; # Pressure is calculated using hydrogen-group based 
pseudo-molecular virial and kinetic energy which results in 
smaller fluctuations. 
useFlexibleCell no ; # Do not allow three orthogonal dimensions of the periodic 
cell to fluctuate independently. 
useConstantRatio no ; # Do not maintain a constant ratio of the unit cell in the x-y 
plane. 
langevinPiston on ; # Turn on Langevin piston pressure control. 
langevinPistonTarget 1.01325 ; # The target pressure for Langevin piston method is 
1.01325 bar. 
langevinPistonPeriod 100 ; # The barostat oscillation time scale for Langevin piston 
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method is 100 fs. 
langevinPistonDecay 50 ; # The barostat damping time scale for Langevin piston 
method is 50 fs. 
langevinPistonTemp $temperature ; # The barostat noise temperature for Langevin 
piston method is the same as the temperature specified in 
temperature control. 
# Output 
outputName $outputname ; Specify the output name for output files. 
restartfreq 1000 ; # Prepare the restart files every 1000 steps (2 ps). 
dcdfreq 1000 ; # The trajectory file is updated every 1000 steps. 
outputEnergies 1000 ; # Output energy to log file every 1000 steps. 
outputPressure 1000 ; # Output pressure to log file every 1000 steps. 
#Harmonic constraints 
constraints on ; # Turn on positional restraints. 
consexp 2 ; # Use 2 as an exponent for constraint energy function 
conskcol B ; # Specify the B factor column of the PDB file to use for the harmonic 
constraint force constant. 
consref constraint.pdb ; # Input the PDB file indicating constraint atoms. 
conskfile constraint.pdb ; # Input the PDB file to use for force constants for harmonic 
constraints. 
## Extra Parameters 
# Periodic Boundary Conditions  
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cellBasisVector1 80.16 0.0 0.0 ; # Specify the x-dimension of the periodic cell size in Å. 
cellBasisVector2 0.0 63.51 0.0 ; # Specify the y-dimension of the periodic cell size in Å. 
cellBasisVector3 0.0 0.0 64.93 ; # Specify the z-dimension of the periodic cell size in Å. 
cellOrigin 5.26 1.74 16.96 ; # Specify the position of the periodic cell center. 
wrapWater on ; # When water molecules cross a periodic boundary, they are not 
translated to the other side of the periodic cell. 
wrapAll on ; # When a molecule cross a periodic boundary, it is not translated to 
the other side of the periodic cell. 
# PME Particle Mesh Ewald 
PME yes ; # Turn on Particle Mesh Ewald method, an efficient full 
electrostatics method in periodic boundary conditions. 
PMEGridSizeX 90 ; # Number of grid points in X dimension. 
PMEGridSizeY 72 ; # Number of grid points in Y dimension. 
PMEGridSizeZ 72 ; # Number of grid points in Z dimension. 
## Execution Script 
# Minimization 
minimize 10000 ; # Run 10,000 step conjugate gradient energy minimization. 
reinitvels $temperature ; # Reset the temperature according to the temperature 
variable after minimization 
# Molecular Dynamics 
run 7500000 ; # Run molecular dynamics for 7500000 steps, which is equal to 
15000 ps (15 ns) 
  
41 
2.10.1 The CHARMM force field 
The CHARMM (Chemistry at HARvard Macromolecular Mechanics) force fields 
represent a set of widely used force fields in molecular dynamics. The CHARMM19 and 
CHARMM22 force fields are parameterized for proteins, and the CHARMM27 force 
field is parameterized for lipid, DNA, and RNA. A general force field for drug-like 
molecules (CGenFF) covers a wide range of chemical groups.  
The following equation is the potential energy function from CHARMM22 (88): 
Utotal = Ubond + Uangle + Udihedral + UvdW + UCoulomb. The components of the potential energy 
function in this equation contain the energy functions for bond stretching, bond angle 
bending, torsion (dihedral angle), and nonbonded interaction. The nonbonded interactions 
include van der Waals (vdW) energy and electrostatic (Coulomb) energy.  
 
2.11 Data analysis of molecular dynamics results 
Trajectories of MD simulation were visualized and analyzed using the Visual 
Molecular Dynamics (VMD) program V. 1.91. The superposition of molecular structures 
was carried out using Pymol. The root-mean-square deviation (RMSD) values were 
calculated using the VMD RMSD trajectory plug-in. The molecular mechanics energy 
was calculated using the NAMD energy plug-in in VMD. The final molecular mechanics 
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energy is the average of molecular mechanics energy of the last 100 frames (the last 200 
ps simulation). Previous studies demonstrated that HIV-1 protease ligands show 
single-maxima probability density function of energy (13). Therefore, the last 200 ps 
simulation represents a relatively stable protease-ligand complex conformation. 
Hydrophobic solvation energy and electrostatic solvation energy were calculated and 
averaged based on the 10 snapshot coordinates of the last 200 ps simulation.  
 The change in desolvation energy during the binding of protease to its substrate was 
obtained with the following equation, ∆Gsolv = ∆Gdesolvelectrostatic + ∆Gdesolvnonpolar. The 
electrostatic desolvation energy was calculated using the Adaptive Poisson-Boltzmann 
Solver (APBS) program (89), a software package for modeling biomolecular solvation 
through solution of the Poisson-Boltzmann equation (PBE). The electrostatic desolvation 
energy upon protease-substrate complex formation was calculated using the following 
equation, ∆Gdesolvelec = ∆∆Gsolvelec  = ∆Gsolvelec,complex – ∆Gsolvelec,protease – ∆Gsolvelec,substrate. The 
symbol ∆Gsolv refers to the difference of solvation energy when a molecule is transferred 
from water solution (with a dielectric constant of 78.54) to vacuum (with a dielectric 
constant of 1.00). The symbol ∆∆Gsolvelec represents the solvation energy change 
(desolvation energy) upon protease-substrate complex formation. The input for the APBS 
program was prepared by converting the PDB format coordinate to PQR format through 
the PDB2PQR server (http://propka.ki.ku.dk), an automated pipeline for the setup, 
execution, and analysis of Poisson-Boltzmann electrostatics calculations (90). The 
PDB2PQR server adds charge and radius parameters to existing PDB data. The non-polar 
desolvation energy was calculated using the equation ∆Gdesolvnonpolar = –∆Gsolvnonpolar = – 
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(γ∆SASA + β), where SASA stands for solvent accessible surface area, γ is a standard 
value of 0.00542 kcal*mol−1*Å−2, and β is 0.92 kcal mol−1 (91). The change of solvent 
accessible surface area upon protease-substrate complex formation is calculated using the 
following equation, ∆SASA = SASAcomplex – SASAprotease – SASAsubstrate. 
2.12 Determination of representative sequences for genotype 4, 5 and 
6 HCV NS3/4 proteases 
All available NS3/4A protease sequences from the HCV database (http://hcv.lanl.gov) 
were aligned using the ClustalW2 program (http://www.ebi.ac.uk/Tools/clustalw2) to find 
a patient isolate sequence that is closest to the consensus sequence of each HCV genotype. 
That patient isolate sequence was selected as the representative for a particular HCV 
genotype. 
2.13 Expression of the NS3/4A proteases of the HCV genotype 4, 5, 
and 6 
Based on the representative sequences of the HCV genotype 4 to 6, the fusion genes 
were constructed with the residues 3-181 of NS3 protein and the residues 21-32 of NS4A 
protein fused to the N-terminus of NS3 protease domain. Therefore, the HCV NS3/4A 
protease maintains an active form without the need for the addition of a separate NS3/4A 
peptide. Between NS4A and NS3, there is a four-residue flexible GSGS linker. Since the 
essential fragment (residue 21-32) of the NS4A peptide has been identified (92), and 
previous studies showed that the fusion protein containing NS4A (residue 21-32), NS3 
(residue 3-181) and a tetrapeptide linker (GSGS) exhibited the full proteolytic activity 
(93), the fusion protein is used in this study to facilitate enzyme assays and crystallization 
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studies later on. For the final constructs, the NS3/4A fusion genes were inserted into the 
plasmid pET28b(+) which produced a 21-residue thrombin cleavable His-tag 
(MGSSHHHHHHSSGLVPRGSHM) at the N-terminus. The 216 amino acid fusion 
proteins (~23 kDa) with NS3 protease domain, a fragment of the NS4A protein, the 
GSGS linker, and the thrombin cleavable His-tag were expressed and purified by 
AnaSpec, Inc. (San Jose, CA). The thrombin cleavable His-tag was kept in the final 
protein since studies conducted at AnaSpec, Inc. showed an increased enzyme activity by 
keeping the tag. 
2.14 HCV protease inhibition essays 
The enzyme inhibitory activity of telaprevir, IC50, for HCV NS3/4A protease from 
genotype 4 to 6 was evaluated. HCV protease FRET substrate S-1 was purchased from 
AnaSpec, Inc. The fluorescence emitted by the peptide cleavage was monitored by 
microplate reader (SpectraMax M5, Molecular Devices) using the excitation wavelength 
355 nm and the emission wavelength of 495 nm. There is no intermolecular quenching of 
the FRET peptide observed in the concentration range of 0.5 to 7.0 µM. The optimized 
concentration of protease was obtained by adjusting the FRET substrate cleavage speed to 
0.08 RFUs/sec. The experiments were conducted in a 96-well plate, with each well 
containing a constant amount of NS3/4A protease in the assay buffer and varying 
concentrations of the serially diluted telaprevir. After a 1 hour incubation at 37°C to form 
the tight enzyme-inhibitor complex-telaprevir being a slow, tight-binding inhibitor – the 
reaction was initiated by the addition of the FRET substrate S1 (final concentrations of 5 
µM S1, 2% (vol/vol) DMSO, total assay volume was 100 µl). The reason for 
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slow-binding inhibition by telaprevir is not known. In contrast, incubation of the HIV-1 
protease with any of the licensed drugs prior to substrate addition is not needed. The 
progress of the HCV NS3 reactions was monitored over 20 min using a sampling rate of 1 
min. The FRET substrate cleavage rates (initial velocities) of the NS3/4 protease with 
serially diluted telaprevir were plotted as data points with the software of SoftMax Pro V. 
5.2.  
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CHAPTER 3 DESIGN AND SYNTHESIS OF A 
MULTI-DRUG RESISTANT HIV-1 PROTEASE 
INHIBITOR BASED ON LOPINAVIR 
 
3.1 Introduction 
Developing novel HIV-1 protease inhibitors that overcome drug-resistance is still a 
challenging task. In drug development, it is difficult to keep pace with the emergence of 
drug resistance. Compared to de novo drug design, drug modification and optimization 
could lower the risk of failure in clinical trials. The modification of available protease 
inhibitors according to the MDR HIV-1 protease isolate may provide a solution to 
overcome drug resistance. Lopinavir is a second-generation protease inhibitor, which is 
derived from ritonavir. The smaller P2 and P2’ groups of lopinavir decrease the contact 
with highly variable residues at the 82 site HIV-1 protease and improve the inhibitory 
efficacy against drug-resistant mutants of HIV-1 protease (19). The MDR HIV-1 protease 
isolate 769 exhibits cross resistance to HIV-1 protease inhibitors. Though lopinavir 
inhibits MDR 769 with a low relative resistance, further modification of lopinavir may 
improve its efficacy against drug resistance mutations in the HIV protease. A mutagenesis 
experiment has been recently completed in our laboratory. The P1 and P1’ groups of the 
HIV-1 protease substrate CA/p2 possessing a reduced scissile peptide bond have been 
mutated and tested for HIV-1 protease inhibition. Compared to a 
phenylalanine-phenylalanine combination at P1 and P1’ sites, the combination of leucine 
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at the P1 site and phenylalanine at the P1’ site exhibits relatively high inhibitory efficacy 
and reduced relative resistance against MDR769 (unpublished data). The current first line 
protease inhibitor, darunavir, also contains the asymmetric combination of leucine side 
chain and phenylalanine side chain at the P1’ and P1 sites (28). However, lopinavir carries 
the symmetric P1 and P1’ groups mimicking the phenylalanine side chain. Therefore, by 
changing the P1 site of lopinavir from a phenylalanine side chain to a leucine side chain 
(isobutyl group), the inhibitory potency of the modified lopinavir may increase and the 
relative resistance against MDR protease may decrease.  
In this chapter, the synthesis, inhibitory potency, and binding mechanism of a 
lopinavir analog with isobutyl P1 group is discussed. The lopinavir analog lowers the 
relative resistance against an MDR HIV-1 protease variant. Simulation results indicate 
that the lopinavir analog induces an asymmetric movement of the 80s loop of the MDR 
HIV-1 protease and this analog exhibits a stronger interaction energy. 
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CA/p2 (P1F, P1’F) reduced peptide 
 
CA/p2 (P1’F) reduced peptide 
      
lopinavir                            lopinavir analog 
 
darunavir 
Figure 3.1 Chemical structures of compounds discussed in Chapter 3. The reduced 
peptide bonds, P1, and P1’ groups are labeled in the figure. 
P1’ 
P1’ 
P1’ P1’ 
P1’ 
P1 
P1 P1 
P1 
P1 
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3.2 Results 
3.2.1 Isobutyl P1 lopinavir analog reduced the relative resistance against the MDR 
HIV-1 protease 769 
 A lopinavir analog with isobutyl P1 group was chemically synthesized according to 
the synthesis procedure of lopinavir (Figure 2.1). The modified step was the Grignard 
reaction, where 1-chloro-2-methyl propane was used to replace benzyl chloride in order 
to introduce a leucine side chain rather than a phenylalanine side chain to the lopinavir 
analog. The original lopinavir was synthesized in parallel as a control. The final lopinavir 
analog was verified using electrospray mass spectrometry (Figure 3.2). The major 
impurity is an intermediate product. 
The IC50 of lopinavir analog with an isobutyl P1 group was determined and listed in 
Table 3.1. The IC50 of the synthesized original lopinavir control and the CA/p2 reduced 
peptide (P1’F) were also measured. The lopinavir analog achieved 50% inhibition of the 
WT HIV-1 protease and MDR 769 at the concentration of 2.1±0.1 nM and 6.8±0.4 nM, 
respectively. The inhibition efficacy of the lopinavir analog was higher than the lopinavir 
control synthesized in parallel which exhibited the IC50 values of 2.5±0.5 nM and 16±0.6 
nM for the WT HIV-1 protease and MDR 769, respectively. Furthermore, the lopinavir 
analog decreased the relative drug resistance from 6.4 to 3.2. The CA/p2 reduced peptide 
still showed the lowest IC50 value (4.4±0.2 nM) inhibiting the MDR HIV-1 protease as 
well as having the lowest relative resistance (1.7 fold). 
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Table 3.1 IC50 results with the lopinavir analog 
Compounds (nM) 
HIV-1 protease Relative 
resistance NL4-3  MDR 769 
Synthesized lopinavir analog 2.1±0.1 6.8±0.4 3.2 
Synthesized lopinavir control* 2.5±0.5 16±0.6 6.4 
Reduced CA/p2 (P1’F) peptide 2.6±0.4 4.4±0.2 1.7 
Reduced CA/p2 (P1F, P1’F) peptide 30.7 142 4.6 
*The lopinavir control was synthesized in parallel using the same procedures and 
equipments. The only different reagent is benzyl chloride instead of 1-chloro-2-methyl 
propane. 
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Figure 3.2 Electrospray mass spectrometry results of the lopinavir analog. Samples were analyzed with K+, Li+, and Na+ ions. 
+ H+ HN
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3.2.2 Asymmetric P1 and P1’ groups induce asymmetric 80s loop conformations of 
the MDR HIV-1 protease 769 
The combination of isobutyl and benzyl group as P1 and P1' sites could induce an 
asymmetric movement of the mobile 80s loops of the HIV-1 protease. By examining the 
co-crystal structures of CA/p2 or darunavir with MDR 769 A82T, the P1 leucine residue 
of CA/p2 peptide and the P1’ isobutyl group of darunavir brought the Pro 81 residue on 
the 80s loop of HIV-1 protease closer to the ligand. In Figure 3.3, the MDR 769 
82T-CA/p2 complex crystal structure and MDR 769 82T-darunavir complex crystal 
structure were superimposed to a WT HIV-1 protease-lopinavir complex crystal structure. 
Compared to the protease 80s loops interacting with the symmetric P1 and P1’ benzyl 
groups of lopinavir, the P1 leucine of CA/p2 peptide brought the protease 80s loop closer 
to the P1 group (Figure 3.3 A) while the phenylalanine P1’ group of the CA/p2 peptide 
induced a similar loop conformation as that of the lopinavir complex (Figure 3.3 B). The 
asymmetric conformations of protease 80s loops have also been observed in the MDR 
769 82T-darunavir complex due to the asymmetric P1 (benzyl) and P1’ (isobutyl) groups 
of darunavir  
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Figure 3.3 The benzyl and isobutyl groups at P1 and P1’ sites trigger the asymmetric 
80s loop conformation of the MDR HIV-1 protease. (A) The co-crystal structure of 
CA/p2 with MDR 769 82T (grey) was superimposed on the co-crystal structure of 
lopinavir with the WT HIV-1 protease (sliver, PDB 2Q5K). The P1 leucine side chain of 
CA/p2 interacted with the protease and altered the 80s loop conformation of one MDR 
protease monomer. (B) In the CA/p2-MDR 769 structure (grey), the P1’ phenylalanine 
side chain of CA/p2 did not alter the 80s loop conformation of the MDR HIV-1 protease, 
compared to the lopinavir-WT HIV-1 protease co-crystal structure (white). (C) The 
co-crystal structure of darunavir with MDR 769 82T (grey, PDB 3SO9) was 
superimposed to the co-crystal structure of the lopinavir-MDR 769 82T complex (white). 
The P1’ isobutyl group of darunavir triggered a similar conformation of the 80s loop as 
that triggered by the P1 leucine side chain of the CA/p2. (D) The 80s loop conformation 
that interacted with the P1 benzyl group was conserved in the lopinavir-MDR 769 82T 
A B 
C D 
Pro 181 Pro 81 
Pro 181 
Pro 81 
P1 
P1’ 
P1 
P1’ 
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(white) and the darunavir-MDR 769 82T (grey) complex structures.   
3.2.3 Simulation analysis of the lopinavir analog binding to the MDR HIV-1 protease  
The lopinavir and isobutyl P1 lopinavir analog in complex with MDR 769 were 
modeled and simulated for 10 ns. The average conformations of the last 200 ps simulation 
were analyzed for both the lopinavir and lopinavir analog complexes. In the average 
conformation of the MDR 769-lopinavir complex, the asymmetric conformation of 
protease 80s loops was observed as well. One 80s loop of the MDR HIV-1 protease 769 
moved closer to the isobutyl P1 group of the lopinavir analog (Figure 3.4). The 
interaction energy calculated between the inhibitor and protease was listed in Table 3.2. 
The calculated interaction energy suggested that the lopinavir analog interacted with 
MDR 769 stronger (-99.47 kcal/mol) than lopinavir did (-92.39 kcal/mol). The interaction 
energy was increased in both electrostatic interactions and van der Waals interactions. 
 
Figure 3.4 Isobutyl P1 lopinavir analog induces asymmetric 80s loop conformation 
of MDR HIV-1 protease 769. The MDR 769-lopinaivr model is represented in while, 
and the MDR 769-lopinaivr analog model is represented in black. The HIV-1 proteases 
Pro 81 
80s loop 80s loop 
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are shown in ribbon representation while the inhibitors and the proline 81 are shown in 
stick representation.  
Table 3.2 Interaction energy of lopinavir and lopinavir analog with the multi-drug 
resistant HIV-1 protease 769 
Compounds  
Interaction energy (kcal/mol) 
Electrostatic  Van der Waals Nonbonded (total) 
lopinavir analog -37.39±6.55 -62.08±3.57 -99.47±7.45 
lopinavir -32.27±8.57 -60.12±3.76 -92.39±9.34 
3.3 Discussion 
The drug-resistant mutations may increase the flexibility of HIV-1 protease and 
therefore alter the active site conformation to be unfavorable for drug binding. The 80s 
loop is a mutation hot spot of HIV-1 protease, which directly interact with the P1 and P1’ 
group of substrates or drugs. The V82A/C/F/I/L/M/S/T mutations on the loop have been 
identified (15, 94). Both structural analyses and enzymatic results indicate that a smaller 
P1 or P1’ group, such as leucine, brings the 80s loop closer to the ligand and increases 
binding affinity.  
The enzyme inhibitory assays demonstrate the promising role of an isobutyl group at 
the P1 or P1’ position in overcoming drug-resistance. However, due to the limitation of 
purification techniques, neither the lopinavir analog or lopinavir control reach the potency 
of the standard lopinavir that was requested from the NIH AIDS Research and Reference 
Reagent Program. The impurities and stereoisomers mixed in the final products increase 
the IC50 values. 
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 Furthermore, the lopinavir analog does not reach the inhibitory potency of CA/p2 
P1’F reduced peptide against the MDR 769 protease. The potency of CA/p2 P1’F reduced 
peptide may be influenced by the P2’ glutamic acid. Studies have shown that the binding 
efficacy of reduced peptides with a glutamic acid in the P2’ position are pH-sensitive (95). 
Therefore, the electrostatic interactions of the CA/p2 P1’F reduced peptide is superior to 
the hydrophobic lopinavir analog, which explains the relatively lower potency of 
lopinavir analog compared to the CA/p2 P1’F reduced peptide. 
The lopinavir analog with an isobutyl group at the P1 position may serve as an 
HIV-1 protease inhibitor against MDR proteases, especially MDR HIV-1 proteases 
containing mutations on the 80s loops. Currently, genotypic assays are recommended to 
assess resistance in the adult and adolescent guidelines of antiretroviral treatment (28). 
Benefiting from protease gene sequences of patience isolates, the choice of optimal 
regimen could be decided based on the types of drug-resistance mutations. Therefore, 
there is a demand of developing modified protease inhibitors against various groups of 
HIV-1 protease variants.  
3.4 Author’s contribution 
The author synthesized the lopinavir analog and lopinavir control, carried out the 
HIV-1 protease inhibition assays and molecular dynamics simulations. The analysis of the 
results including structure superposition was also carried out by the author.  
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CHAPTER 4 THE HIGHER BARRIER OF DARUNAVIR 
AND TIPRANAVIR RESISTANCE FOR HIV-1 
PROTEASE 
 
4.1 Introduction 
The emergence of drug resistance during antiretroviral therapy is a key concern for 
HIV patients. In patients undergoing combination antiretroviral therapy, protease 
inhibitors are important contributors to the decrease in the number of circulating virus 
particles. In total, nine HIV-1 protease inhibitors have been approved by the US Food and 
Drug Administration (FDA). In the 99 amino acid residue HIV-1 protease, 36 mutation 
loci have been identified which lead to various levels of resistance to protease inhibitor 
treatment (15, 96). The current HIV-1 protease inhibitors are designed with a hydroxyl 
group to mimic the transition state of the substrate’s scissile peptide bond. Due to the 
structural similarity of inhibitors, the mutations in HIV-1 protease are commonly 
associated with cross-resistance to the other inhibitors (94). 
The clinical multi-drug resistant (MDR) HIV-1 strain 769 was isolated by Palmer et 
al. from patients failing protease inhibitor-containing antiretroviral regimens, and the 
protease of strain 769, MDR 769, is resistant to all protease inhibitors tested (97). As 
observed in the crystal structure previously solved by our group, the flaps of MDR 769 
are farther apart compared to the distance of wild-type (WT) HIV-1 protease flaps (98). 
The threonine mutation at residue 82 of the MDR HIV-1 protease (MDR 769 82T) alters 
the hydrophobicity of the P1 and P1’ binding pockets and could further enhance 
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cross-drug resistance. The uncomplexed MDR 769 82T crystal structure adopts the 
wide-open flap conformation as reported earlier for MDR 769 (98, 99).  
According to virologic response studies, darunavir and tipranavir show a higher 
genetic barrier to resistance (100). Both inhibitors have been used to treat patients 
infected with protease inhibitor-resistant viral strains and have effectively inhibited a 
range of MDR protease isolates (101-103). Based on the scoring function of the HIV 
Drug Resistance Database (http://hivdb.stanford.edu), MDR 769 82T has low resistance 
to darunavir and high resistance to tipranavir as well as the other seven protease inhibitors 
(15, 96).  
The structural study of the inhibitor-bound MDR HIV-1 protease facilitates the 
understanding of drug resistance mechanisms. The aim of this study is to test the in vitro 
inhibitory potency of darunavir and tipranavir against MDR 769 82T and to determine the 
mechanism of overcoming resistance by examining the binding conformation, key 
contacts, and the stability of inhibitor-protease complexes. The protease inhibition assays 
demonstrate the decreased susceptibility of MDR 769 82T to all the tested inhibitors and 
confirm that 82T severely enhances drug resistance. Compared to other protease 
inhibitors, the higher resistance barrier of darunavir is due to maintaining main chain 
hydrogen bonds by inhibitor flexibility while the higher resistance barrier of tipranavir is 
due to tight flap binding. 
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Table 4.1 Sequences of the HIV-1 protease variants 
HIV-1 
protease Sequences
a
 
NL4-3 
PQITLWKRPL VTIKIGGQLK EALLDTGADD TVLEEMNLPG RWKPKMIGGI GGFIKVRQYD QILIEICGHK AIGTVLVGPT 
PVNIIGRNLL TQIGCTLNF 
MDR 769 
PQITLWKRPI VTIKIGGQLK EALLDTGADD TVLEEVNLPG RWKPKLIGGI GGFVKVRQYD QVPIEICGHK VIGTVLVGPT 
PANVIGRNLM TQIGCTLNF 
MDR 769 82T 
PQITLWKRPI VTIKIGGQLK EALLDTGADD TVLEEVNLPG RWKPKLIGGI GGFVKVRQYD QVPIEICGHK VIGTVLVGPT 
PTNVIGRNLM TQIGCTLNF 
aThe drug resistant mutations are in bold and polymorphic changes are underlined.
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Table 4.2 IC50 measurements and relative resistance 
Inhibitor 
IC50 (nM) Relative resistance Predicted 
resistance scorea 
WT (NL4-3) MDR 769 MDR 769 82T 
MDR 
769 
MDR 769 
82T 
MDR 
769 
MDR 
769 82T 
darunavir 0.26 ±0.024 0.74 ±0.20 2.76 ±0.16 2.8 11 10 10 
tipranavir 0.24 ±0.18 0.63 ±0.17 3.02 ±0.10 2.6 13 24 64 
lopinavir 0.28 ±0.27 0.50 ±0.060 3.18 ±0.23 1.8 11 76 76 
amprenavir 0.43 ±0.044 4.82 ±0.90 7.87 ±0.16 11 18 86 86 
atazanavir 0.19 ±0.071 2.90 ± 0.16 10.8 ±0.40 15 57 98 103 
nelfinavir 1.58 ±0.85 109 ±5.0 448 ±65 69 2.8×102 184 184 
ritonavir 0.34 ±0.15 60.7 ±3.5 237 ±5.6 180 7.0×102 - - 
saquinavir 0.50 ±0.017 294 ±9.4 1.30×103 ±87 590 2.6×103 114 114 
indinavir 0.47±0.19 119 ± 13 307 ±29 250 6.5×102 128 128 
aThe resistance scores for darunavir, tipranavir, lopinavir, amprenavir, atazanavir, saquinavir, and indinavir were predicted based on the protease 
inhibitor plus ritonavir co-administration. The larger scores indicate higher predicted resistance.
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4.2 Results 
4.2.1 Darunavir and tipranavir presented high barrier of resistance compared to the 
other protease inhibitors 
The nine FDA-approved HIV-1 protease inhibitors were effective against the WT 
HIV-1 protease, NL4-3, at low nanomolar or sub-nanomolar concentration while the 
MDR 769 82T was resistant to all nine inhibitors (Table 4.2). The resistance ranged from 
11-fold to 2600-fold as compared with the inhibition level against NL4-3. Although 11-13 
relative resistance was observed, darunavir and tipranavir were the two most potent 
inhibitors against MDR 769 82T. Based on the IC50 values, the difference in Gibbs free 
energy (∆∆G) values calculated with the IC50 of MDR 769 82T and WT HIV-1 protease 
were -1.48 kcal/mol and -1.58 kcal/mol for darunavir and tipranavir, respectively. 
The 82T mutation of the MDR protease greatly enhanced drug resistance. The 
relative resistance of the MDR 769 (1.8-590 fold) was approximately 2.6-6.1 times lower 
compared to that of MDR 769 82T. The 82T mutation caused relatively larger differences 
in the relative resistance of darunavir, tipranavir, and lopinavir, and the relative resistance 
was elevated 3.9, 5.0, and 6.1 times, respectively. The IC50 values are not fully correlated 
with predicted values based on the scoring of inhibitor resistance mutations from the HIV 
Drug Resistance Database since the 82T mutation has not been reported previously as 
darunavir resistance mutation (104). 
4.2.2 Darunavir or tipranavir induced flap closure of the MDR HIV-1 protease 
The darunavir-MDR 769 82T and tipranavir-MDR 769 82T co-crystal structures 
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were determined at a resolution of 1.24 Å and 2.87 Å, respectively. The binding of 
tipranavir or darunavir effectively closed the wide-open flap of the MDR protease and 
exhibited a conserved binding mode in the MDR protease relative to that in the wild-type 
protease. The tipranavir-MDR 769 82T complex crystallized in the hexagonal space 
group P61. The darunavir-MDR 769 82T complex crystallized in the orthorhombic space 
group P212121. The diffraction and refinement statistics are shown in Table 4.3. The 
structures were deposited in the Protein Data Bank. The PDB IDs for darunavir-MDR 769 
82T and tipranavir-MDR 769 82T structures are 3SO9 and 3SPK, respectively. Compared 
with the binding of darunavir or tipranavir to the WT HIV-1 protease (PDB ID: 3BVB 
and 2O4P), the butyl group of tipranavir and the P1’, P2, and P2’ groups of darunavir 
adopted different conformations relative to their binding to WT HIV-1 protease (Figure 
4.1 A and B).  
Asymmetric movement of the 80s loop regions was observed in the darunavir-MDR 
complex. The RMSD of Thr 82 of superimposed protease monomers is 1.318 Å. The 
asymmetric P1 and P1’ group of darunavir induced the asymmetric protease dimer. The 
smaller isobutyl P1’ group of darunavir allowed the 80s loop of the MDR protease to 
move closer to the inhibitor. According to the superposition of MDR 769 82T and WT 
HIV-1 protease structures, Pro 81 in one monomer of the MDR protease was 0.7 Å closer 
to the isobutyl P1’ group of darunavir. Thr 82 was 1.6 Å further from the isobutyl P1’ 
group of darunavir compared to Val 82 in WT HIV-1 protease (Figure 4.1 B). The V82T 
mutation changed the hydrophobicity of the binding pocket in the MDR protease. 
Therefore, the hydrophilic Thr 82 pointed toward the solvent rather than the hydrophobic 
  
63 
binding pocket. The 80s loop on the other monomer of the MDR protease showed an 
asymmetric pattern. Both Pro 81 and Thr 82 moved away from the benzyl P1 group of 
darunavir.  
Table 4.3 Crystallographic statistics 
Dataset Tipranavir-MDR 
769 82T co-crystal  
Darunavir-MDR 769 
82T co-crystal  
Data collection   
Space group P61 P212121 
Wavelength (Å) 0.979 0.979 
Cell constants (Å) a=63.12 b=63.12 
c=83.54 
a=28.90 b=66.38 
c=90.84 
Resolution range (Å) 29.52-1.24 (1.25-1.24) 30.00-2.87 (2.95-2.87) 
Number of unique reflections 51613 (1138) 10515 (195) 
Completeness (%) 96.7 (70.9) 98.4 (100.0) 
Redundancy 9.1 (2.7) 4.4 (4.5) 
Mean I/σ (I) 13.4 (1.2) 11.4(3.6) 
Rmerge a 0.084 (0.679) 0.142 (0.486) 
Refinement   
Rwork (%)b 17.40 21.65 
Rfree (%)b 22.70 25.62 
Number of atoms   
          Ligand 42 38 
          Protease 1514 1514 
          Solvent 351 142 
Average B factor (Å2)   
          Ligand 10.91 35.67 
          Protease 13.38 18.58 
          Solvent 37.16 27.95 
RMSD bond length (Å) 0.010 0.009 
RMSD bond angle (°) 1.37 1.03 
Ramachandran plot   
Allowed/generous/disallowed (%) 94.9/5.1/0 92.9/7.1/0 
aRmerge= Σhkl Σi |Ii (hkl) - <I(hkl)>| / Σhkl Σi Ii(hkl), where Ii (hkl) is the intensity of an 
observation and I(hkl) is the mean value for its unique reflection. 
bRwork =Σhkl ||Fo|−|Fc|| / Σhkl |Fo|, where Fo and Fc are the observed and calculated structure 
factor amplitudes. Rfree is calculated exactly as Rwork using a random 5% of the reflections 
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omitted from refinement.  
 
 
Figure 4.1 Co-crystal structures of darunavir and tipranavir with the MDR protease. 
(A) The tipranavir-MDR 769 82T structure (magenta) was superimposed on the 
tipranavir-WT HIV-1 protease structure (green). The I54V mutation is displayed in stick 
model. The magenta and green dashed lines indicate the distance (Å) between the 
inhibitor and the MDR HIV-1 protease or the WT HIV-1 protease, respectively. (B) The 
conformational changes of darunavir binding to MDR 769 82T (magenta) in comparison 
with the darunavir-WT HIV-1 protease complex (green). (C) The electron density of 
tipranavir bound to MDR 769 82T protease is shown as an Fo –Fc OMIT map contoured 
at 2σ. Two tipranavir molecules (yellow and magenta) binding in different orientation are 
presented. (D) The electron density of darunavir bound to MDR 769 82T protease is 
shown as an Fo –Fc OMIT map contoured at 2σ. 
A B 
C D 
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4.2.3 Specific contacts were lost between darunavir or tipranavir and the MDR 
HIV-1 protease 
Hydrophobic interactions or hydrogen bonds were lost between the inhibitors and the 
MDR protease. According to the LIGPLOT analysis, the number of residues in MDR 769 
82T involved in hydrophobic interactions with darunavir or tipranavir decreased by 1~2 
residues compared to that of WT HIV-1 protease. Tipranavir lost hydrophobic interactions 
with Gly 49, Val 32, and Val 84 of the MDR protease but gained additional hydrophobic 
interactions with Thr 82. Similarly, darunavir failed to maintain hydrophobic interactions 
with Pro 81 and Ile 84 of the MDR protease but gained hydrophobic contacts with Leu 23. 
The hydrogen bonding network of tipranavir was generally preserved (Figure 4.2). 
Tipranavir formed hydrogen bonds with Asn 25, Asp 29, Asp 30, Gly 48, and Ile 50. 
Except for the hydrogen bonds formed between the hydroxyl group of tipranavir and the 
catalytic residues of the protease, all other hydrogen bonds were formed on the main 
chain of the protease. Darunavir lost one hydrogen bond and altered the bonding of 
another hydrogen bond in the darunavir-MDR 769 82T complex structure. The bicyclic 
tetrahydrofuran P2 group of darunavir formed a pair of hydrogen bonds with Asp 29 of 
WT HIV-1 protease. In the MDR protease complex, the dislocation of the P2 group of 
darunavir causes it to lose one hydrogen bond with Asp 29 (Figure 4.2). The dislocation 
of the sulfonamide P2’ group lost the hydrogen bond with the carboxyl group of the Asp 
29 side chain, but the P2’ group formed a new hydrogen bond with the carbonyl group of 
the Asp 29 main chain (Figure 4.2).  
 
  
66 
 
Figure 4.2 Hydrogen bonds and hydrophobic interactions of tipranavir and 
darunavir with MDR 769 82T protease. Hydrogen bonds are shown as green dashed 
lines. The residues that form hydrophobic interactions with tipranavir are illustrated by 
spokes. The interaction map was produced using LIGPLOT V4.5.3. 
4.2.4 Tipranavir elevated the melting temperature of the protease-inhibitor complex 
suggesting enhanced stability 
The melting temperatures of the apo-MDR 769 82T and the MDR 769 82T in 
complex with inhibitors were determined using differential scanning fluorimetry. While 
eight protease-inhibitor complexes displayed a similar melting temperature to that of the 
apo-MDR 769 82T (50.8 ± 0.6 °C), the tipranavir-MDR 769 82T complex shifted the 
melting temperature to a higher value (62.0 ± 2.6 °C). The melting temperature of the 
darunavir-protease complex was 52.6 ± 0.8 °C. The difference between the melting 
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temperatures of the two complexes was 9.4 °C suggesting that tipranavir stabilized the 
protease-inhibitor complex (Figure 4.3).  
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Figure 4.3 The tipranavir-MDR 768 82T complex showed higher denaturation 
temperature compared to the darunavir-MDR 769 82T complex. The X-axis is 
temperature in Celsius degree, and the Y-axis is fluorescence change in Relative 
Fluorescence Units (RFU).  
4.3 Discussion 
The objective of this study is to investigate how darunavir and tipranavir maintain 
their inhibitory efficacy against MDR HIV-1 protease. Darunavir preserves its residual 
inhibitory efficacy by forming altered hydrogen bonds while tipranavir overcomes drug 
resistance by stabilizing the protease-inhibitor complex through direct interactions with 
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the protease flaps. 
The valine to threonine mutation at residue 82 is an isosteric switch that alters the 
hydrophilic environment of the S1 and S1’ binding pocket in the protease and greatly 
enhances the relative resistance to inhibitors. The valine to alanine mutation in MDR 769 
is a change from a longer side chain to a shorter side chain, but the hydrophobicity of this 
mutation is preserved. In both darunavir and tipranavir MDR 769 82T complex structures, 
the Thr 82 residue moves away from the binding pocket towards the hydrophilic solvent 
environment exhibiting greater relative resistance than the Ala 82 mutation. Darunavir, 
tipranavir, and lopinavir inhibit the MDR 769 at sub-nanomolar concentration; however, 
they only inhibit MDR 769 82T at approximately 3 nM. Therefore, the hydrophobicity 
change in the binding pocket is more severe than contact loss in the binding pocket.  
Darunavir or tipranavir binding to MDR 769 82T effectively triggers the protease flap 
closure. MDR 769 82T tends to maintain the wide-open form even in the presence of 
other inhibitors (105). The wide-open form of MDR 769 82T is possibly due to the fact 
that M46L and I54V disrupt the rigid β-sheet of the protease flaps and therefore increase 
the flexibility of the flaps.  
Tipranavir, the only FDA-approved non-peptidomimetic HIV-1 protease inhibitor, 
does not form the same hydrogen bonds with the flaps through a bridging water molecule 
as peptidomimetic inhibitors do. Instead, tipranavir forms a hydrogen bond directly 
between the carbonyl group of tipranavir and the Ile 50 residue on each MDR protease 
flap. The DSF results indicate that tipranavir greatly stabilizes the inhibitor-protease 
complex. Therefore, tipranavir may partially overcome drug resistance of the MDR 
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protease by tightly closing the protease flaps.  
Two possible drug design strategies could be considered to improve the potency of 
inhibitors against MDR proteases based on the advantageous characteristics of darunavir 
and tipranavir that elevate the resistance barrier to MDR protease. The first strategy is to 
design chemical groups that make direct contact with the flap residues of MDR proteases 
rather than mimicking substrates to interact with flaps via a bridging water molecule. 
Stronger interactions between the inhibitor and protease flaps decrease the probability of 
the protease-inhibitor complex dissociation. The hydrogen bonds formed directly between 
the flap residue Ile50 and tipranavir reduce the protease flap flexibility caused by the 
mutations, demonstrating the stability of the tipranavir-MDR protease complex. 
The second strategy to improve the potency of inhibitors against MDR proteases is to 
design inhibitor interactions with the main chain of the HIV-1 protease by flexible 
pharmacophores. When the carboxyl group of Asp 29 is far away from the sulfonamide 
P2’ group of darunavir, the P2’ group preserves a hydrogen bond with the main chain 
carbonyl group of Asp 29 (Fig. 2). The main chain hydrogen bonds contribute to the 
ability of darunavir to overcome drug resistance conferred by protease active site 
mutations (106). Other than the P2 group, the darunavir structure is identical to 
amprenavir. The flexible bicyclic tetrahydrofuran P2 group of darunavir enhances the 
hydrogen bond forming propensity relative to amprenavir (27). According to the 
darunavir-MDR 769 82T complex, the P2 group of darunavir adopts a different 
conformation relative to the darunavir-WT HIV-1 protease complex but preserves 
hydrogen bonds with the main chain of the MDR protease, suggesting that flexible drugs 
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favorably form contacts in the HIV-1 protease active site cavity and maintain potency.  
In summary, the inhibitor-MDR HIV-1 protease complex structures could serve as models 
for drug optimization. Rather than the de novo design of new inhibitors, optimization of 
existing inhibitors may have a higher chance of success against MDR variants. Minor 
modifications on the protease inhibitors may restore the contacts without affecting the 
bioavailability and toxicity of the molecule. 
4.4 Author’s contribution 
The author conducted the protein expression of the inactive MDR 768 82T, active 
MDR 769 82T, and active MDR 769. The crystallization screening, crystallization setup, 
structure solution, enzyme assays, DSF experiments, and analysis of results were 
performed by the author. The crystal diffraction data collection and initial data processing 
were conducted by Dr. Joseph S. Brunzelle from the Department of Molecular 
Pharmacology and Biological Chemistry, Feinberg School of Medicine, Northwestern 
University, Chicago, IL. 
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CHAPTER 5 IDENTIFICATION OF A LEAD 
COMPOUND TARGETING A MULTI-DRUG RESISTANT 
HIV-1 PROTEASE VARIANT USING VIRTUAL 
SCREENING 
 
5.1 Introduction 
The drug-resistance mutations accumulated in the HIV-1 protease during 
antiretroviral therapy change the protease structure and decrease the efficacy of protease 
inhibitors. Since most HIV-1 protease inhibitors were designed to mimic the substrate 
cleavage intermediate, structurally diverse inhibitors are needed to maintain efficacy 
against the highly flexible protease (107). The discovery of new inhibitor scaffolds is the 
first step to enrich the diversity of HIV-1 protease inhibitors. The HIV-1 protease 
structures greatly facilitate the discovery of new inhibitors.  
Few ligand-free three-dimensional structures of HIV-1 protease have been deposited 
to the Protein Data Bank. We have previously reported one such structure of an 
uncomplexed MDR HIV-1 protease, MDR 769 (108). As shown in Figure 5.1, the 
available ligand-free HIV-1 protease can be classified into two classes, wide-open form 
and curled form (109). Considering the flexibility and dynamic movement of the protease, 
the structures of the uncomplexed HIV-1 protease are as important as the ligand-bound 
structures needed for successful drug design. 
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Figure 5.1 The flap conformations of apo HIV-1 protease structures. The structures 
include the WT HIV-1 protease NL4-3 (PDB ID: 2HB4, blue), the MDR HIV-1 protease 
with mutations L24I, M46I, F53L, L63P, V77I, and V82A (PDB ID: 2HB2, magenta), the 
WT HIV-1 protease isolate BRU (PDB ID: 1HHP, yellow), another WT HIV-1 protease 
(PDB ID: 2PC0, green), and the MDR HIV-1 protease 769 with mutations L10I, M36V, 
M46L, I54V, I62V, L63P, A71V, V82A, I84V, and L90M (PDB ID: 1TW7, orange) 
 
Understanding the structural diversity of the target protease is essential for inhibitor 
development. The plasticity of the HIV-1 protease flap region is critical in binding 
substrates and inhibitors (109). The increased flap flexibility may enhance drug 
cross-resistance by altering the binding pocket of protease inhibitors. Flap movement 
distorts the binding cavity and therefore reduces the binding affinity to inhibitors. Direct 
measurement using pulsed double electron-electron resonance (DEER) has confirmed a 
larger distance between the flaps of MDR HIV-1 protease as compared to the wild-type 
structure (110). Therefore, the wide-open form of HIV-1 protease can serve as a 
nontraditional model to develop inhibitors targeting the open form protease. A crystal 
structure has shown that the HIV-1 protease with open-flap conformation binds two 
Curled form 
Wide-open form 
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symmetric pyrrolidine diester inhibitors (111). The range of opening and conformational 
flexibility of the protease flaps demonstrate the importance of protein flexibility in 
structure-based drug design. Using ensembles of protein conformations as receptors for 
docking is a powerful method to increase accuracy (112, 113). Docking inhibitors based 
on both the open and closed form of HIV-1 MDR protease partially represents the HIV-1 
protease dynamics and improves the adaptation of the drug to the flexible movement of 
the protease. 
5.2 Results 
The commercially-available compound libraries of TimTec Inc., Adesis Inc., and 
Enamine Ltd. from the ZINC database (http://zinc.docking.org/) were initially screened 
using LASSO (Ligand Activity in Surface Similarity Order) 2009 (82). Thousands of 
compounds were selected to generate a smaller library for further validation using eHiTS 
docking (82). The open form MDR HIV-1 protease 769 structure was used as a receptor 
to identify potential inhibitor scaffolds. One compound, GR346 (Figure 5.2), showed the 
best docking scores against the open form MDR 769 protease. 
 
Figure 5.2 Chemical structure of compound GR346. 
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Figure 5.3 Docking conformation of GR346 in the active site of MDR 769 HIV-1 
protease. (A) GR346 was docked to the wide-open form MDR 769. (B) GR346 was 
docked to the closed form MDR 769 HIV-1 protease. The blue lines represent possible 
hydrogen bonds. 
 
Figure 5.4 HIV-1 protease inhibition by the compound GR346. The MDR 769 
protease is inhibited more than the wild type (NL-43) by GR346. 
 
The binding of GR346 was examined by docking it to the closed and wide-open 
forms of the MDR 769 protease using AutoDock4 (83). The docking conformation of 
GR346 is shown in Figure 5.3. GR346 was originally synthesized as an NAD-dependent 
A B 
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deacetylase sirtuin-2 (SIRT2) inhibitor (IC50=56.7 µM) (114). The HIV-1 protease 
inhibitory efficacy was tested using an in vitro enzyme assay (Figure 5.4). GR346 
inhibited a larger percentage of MDR 769 enzyme activity at various concentrations 
compared to its inhibition of the WT HIV-1 protease. At the lower compound 
concentration (6.25 µM), GR346 did not inhibit the WT HIV-1 protease but it did inhibit 
the MDR 769 activity by 10%. The wide-open conformation of the MDR 769 flaps 
allowed the bulky compound, GR346, to easily enter the protease active site cavity. This 
result suggests the possibility that larger inhibitors could fit better in the expanded active 
site of MDR HIV-1 protease. 
5.3 Discussion 
The virtual screening experiments in this chapter have the goal of identifying a novel 
scaffold as an HIV-1 protease inhibitor. GR346 with micromolar IC50 is a good lead 
compound from screening. The novel protease inhibitor scaffold could be further 
modified and developed to improve potency. A promising finding is the selective 
inhibition of GR346 against MDR HIV-1 protease at lower concentration. The protease 
inhibition assay of GR346 suggests the different ligand preference between MDR HIV-1 
protease and WT HIV-1 protease. Thus, it is possible to develop MDR HIV-1 protease 
specific inhibitors for AIDS patients who fail regular HIV-1 protease inhibitor treatment. 
The selective binding of GR346 to the MDR HIV-1 protease may be due to the flexibility 
of the MDR protease flaps. The wider inter-flap distance increases the accessibility of 
bulky compounds.  
Protein flexibility is an important feature in drug design. Designing drugs that make 
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contacts with the protease flaps to reduce protease flexibility, and targeting the open form 
protease could be options to overcome drug resistance caused by protease flap 
conformation and flexibility. 
 
5.4 Author’s contribution 
The author performed the virtual screening, docking experiments, enzyme assays, 
and the analysis of the data. 
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CHAPTER 6 A HIGHER DESOLVATION ENERGY 
REDUCES LIGAND RECOGNITION IN MULTI-DRUG 
RESISTANT HIV-1 PROTEASE 
 
6.1 Introduction 
Developing novel HIV-1 protease inhibitors is a current requirement to keep pace 
with the emergence of drug resistance mutations in the HIV-1 protease. Most of the 
current HIV-1 protease inhibitors are designed based on substrate mimicking. In addition 
to mimicking the transition state of the substrate cleavage, inhibitors designed based on 
the consensus volume of substrates have been developed (115). The consensus volume of 
various substrates is defined as the substrate envelope. The HIV-1 protease substrate 
envelope has been determined based on the protease-substrate co-crystal structures (116). 
A more realistic dynamic model of the substrate envelope has been refined using 
molecular dynamics of HIV-1 protease-substrate complex structures (117). The study of 
the substrate binding to various HIV-1 protease variants, especially drug-resistant variants, 
facilitates the development of drugs inhibiting a broad panel of HIV-1 protease variants. 
The accumulated drug-resistance mutations in the protease may alter the subsites of the 
active site cavity, and therefore the inhibitor binding affinity alters accordingly. Studies 
have shown that the substrate analog inhibitors contact the same set of residues of HIV-1 
protease as the natural substrates do (118). Therefore, MDR HIV-1 protease variants may 
also change the binding affinity to the substrates.  
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Four clinical MDR HIV-1 protease variants, MDR 769, MDR 807, MDR 1385, and 
MDR 3761, were isolated by Palmer et al (97), among which MDR 769 exhibited 
resistance to all the tested inhibitors (119) and was successfully crystallized. The 
accumulation of drug-resistance mutations also alters the structure of the MDR protease 
variants. The flaps of the apo MDR 769 protease adopt a wide-open conformation (98). 
Based on the available structures and known crystallization conditions, MDR 769 could 
serve as a model for studying the binding patterns of MDR protease variants. 
Peptidomimetic design based on the HIV-1 protease substrates is one of the popular 
drug design strategies. In our study, four clinical isolates of MDR HIV-1 protease variants 
were examined. The four MDR HIV-1 protease variants exhibited resistance to all US 
FDA-approved HIV-1 protease inhibitors, and the substrate recognition ability is also 
reduced in these proteases. In the experiment of the HIV-1 protease substrate-based 
peptides competing with a fluorescent substrate, the substrate recognition of various 
HIV-1 protease variants was illustrated. The results showed different recognition of the 
substrates p2/NC, CA/p2 P1’F, RH/IN, and RT/RH among the five HIV-1 protease 
variants. With the co-crystal structures of p2/NC and CA/p2 P1’F with MDR 769 protease, 
five HIV-1 protease variants in complex with p2/NC and CA/p2 P1’F were modeled and 
simulated to study the binding of substrates in the protease active site cavity. The 
simulation results indicated that the MDR proteases need to overcome the higher 
desolvation energy barrier to form substrate-protease complexes. The binding studies of 
the heptapeptides p2/NC and CA/p2 P1’F can facilitate the identification of subsite 
preference of HIV-1 protease variants and the design of drugs inhibiting a broader range 
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of MDR HIV-1 protease variants.  
 
Table 6.1 Sequences of the HIV-1 protease variants selected 
HIV-1 
protease 
Sequences* 
NL4-3 PQITLWKRPL VTIKIGGQLK EALLDTGADD TVLEEMNLPG RWKPKMIGGI 
GGFIKVRQYD QILIEICGHK AIGTVLVGPT PVNIIGRNLL TQIGCTLNF 
769 PQITLWKRPI VTIKIGGQLK EALLDTGADD TVLEEVNLPG RWKPKLIGGI 
GGFVKVRQYD QVPIEICGHK VIGTVLVGPT PANVIGRNLM TQIGCTLNF 
807 PQITLWKRPI VTIKIGGQLK EALLDTGADD TVLEEMNLPG KWKPKIIVGI 
GGFTKVRQYD NVQIEICGHK VIGAVLIGPT PANIIGRNLL TQLGCTLNF 
1385 PQITLWKRPF VTIKIGGQLK EALLDTGADD TVLEEIDLPG RWKPKIIGGI 
GGFIKVKQYD QIPIEICGHK VIGTVLVGPT PTNIIGRNMM TQLGCTLNF 
3761 PQITLWKRPI VAIKVGGQII EALLDTGADD TVLEEMNLPG RWKPKIIGGI 
GGFIKVRQYD QIPVEICGHK IITTVLVGST PVNVIGRNLM TQLGCTLNF 
*The polymorphic changes are underlined. The drug-resistance mutations are in bold. 
 
Table 6.2 Sequences of the nine HIV-1 protease cleavage sites within the HIV-1 
Gag-Pol polyprotein 
substrate P3 P2 P1 P1’ P2’ P3’ P4’ 
MA/CA Gln Asn Tyr Pro Ile Val Gln 
CA/p2* Arg Val Leu Phe Glu Ala Met 
p2/NC Thr Ile Met Met Gln Arg Gly 
NC/p1 Gln Ala Asn Phe Leu Gly Lys 
p1/p6 Gly Asn Phe Leu Gln Ser Arg 
TF/PR Phe Asn Phe Pro Gln Ile Thr 
PR/RT Leu Asn Phe Pro Ile Ser Pro 
RT/RH Glu Thr Phe Tyr Val Asp Gly 
RH/IN Lys Ile Leu Phe Leu Asp Gly 
The cleavage site is between the P1 and P1’ residue. The CA/p2 contains an alanine to 
phenylalanine mutation at P1’ position. 
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6.2 Results 
6.2.1 The four clinical MDR HIV-1 protease isolates are resistant to all 
FDA-approved HIV-1 protease inhibitors 
The drug-resistance profiles of the four clinical MDR HIV-1 protease isolates were 
identified using enzyme inhibition assays. The four MDR protease variants are resistant to 
all of the FDA-approved HIV-1 protease inhibitors at various levels (Figure 6.1, Table 
6.3). In the table, the HIV-1 protease variant NL4-3 represents a WT HIV-1 protease. 
Regarding to the inhibitory efficacy, the second generation of HIV-1 protease inhibitors 
(tipranavir, darunavir, lopinavir, and atazanavir) encountered lower relative resistance. 
Among the four MDR HIV-1 protease variants, MDR 807 and MDR 1385 were more 
resistant to the second generation HIV-1 protease inhibitors. For the first-line HIV-1 
protease inhibitors (28), higher resistance was observed to atazanavir compared to 
darunavir. These results confirmed the in vitro resistance of the HIV-1 protease clinical 
isolates.  
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Figure 6.1 Relative resistance of the MDR HIV-1 protease variants. The y-axis is 
relative resistance on a logarithmic scale while on the x-axis are the names of the 
FDA-approved HIV-1 protease inhibitors.
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Table 6.3 IC50 and relative resistance of FDA-approved HIV-1 protease inhibitor against HIV-1 protease variants 
HIV-1 
Proteases 
IC50 of HIV-1 protease inhibitors* in nM (relative resistance) 
darunavir atazanavir lopinavir tipranavir nelfinavir amprenavir saquinavir indinavir ritonavir 
NL4-3 0.26 (1) 0.19 (1) 0.28 (1) 0.24 (1) 1.6 (1) 0.43 (1) 0.50 (1) 0.47 (1) 0.34 (1) 
MDR 769 0.74 (2.8) 2.9 (15) 0.50 (1.8) 0.65 (2.7) 110 (69) 4.8 (11) 290 (590) 120 (250) 61 (180) 
MDR 807 2.0 (7.7) 7.6 (40) 1.2 (4.3) 0.63 (2.6) 210 (130) 2.9 (6.7) 850 (1700) 280 (600) 14.6 (43) 
MDR 1385 3.0 (12) 4.6 (24) 2.3 (8.2) 2.8 (12) 230 (140) 3.1 (7.2) 29 (58) 140 (300) 8.0 (24) 
MDR 3761 0.89 (3.4) 2.2 (12) 0.39 (1.4) 0.63 (2.6) 430 (270) 4.1 (9.5) 110 (220) 210 (450) 21 (62) 
*The protease inhibitors were requested from the NIH AIDS Research and Reference Reagent Program (http://www.aidsreagent.org/). 
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6.2.2 The MDR HIV-1 protease isolates exhibited different substrate binding 
preference relative to the WT protease 
Compared to inhibitors, the higher flexibility of substrates could match the dynamic 
changes in the protease (107). The study of substrate binding facilitates the development 
of peptidomimetic inhibitors. In the FRET substrate cleavage interference experiments, 
the five HIV-1 protease variants show varied preferences to the nine heptapeptides. The 
processing ratio in Figure 6.2 represents the ratio of the average FRET substrate 
processing velocity in the presence of the heptapeptide over the average FRET substrate 
processing velocity in the absence of the heptapeptide. The higher ratio indicated less 
interference by the peptide on FRET substrate processing. Both the peptide and the FRET 
substrate were in excess molar ratio to the HIV-1 protease, and the peptide concentration 
was 40-fold higher than the FRET substrate concentration. The rate-limiting step of the 
HIV-1 protease substrate, catalysis, is a chemical process rather than a physical process 
(120). Therefore, interference was caused by the peptide cleavage process rather than the 
peptide binding process. Once a protease-substrate complex is formed, the cleavage of 
FRET substrate is slowed down. The high velocity ratios of the FRET substrate cleavage 
with or without the regular peptide were due to the lower chance of forming 
protease-substrate complex with the peptide. The complex formation theory was 
supported by the enzyme assays using the uncleavable CA/p2 P1’F peptide. The 
inhibition of the uncleavable peptide is correlated with the peptide competition results. 
The IC50 values of CA/p2 P1’F pseudopeptide for NL4-3, MDR 769, MDR 807, MDR 
1385, and MDR 3761 were 2.6 nM, 4.4 nM, 16.0 nM, 32.5 nM, and 55.4 nM, respectively. 
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The corresponding relative resistance values were 1.7, 6.2, 13, and 21 fold, respectively. 
The correlation coefficient between the FRET velocity ratios in presence of CA/p2 P1’F 
and the IC50 values of CA/p2 P1’F pseudopeptide was 0.86. 
The ratios of heptapeptide interference exhibited the likelihood of protease-substrate 
complex formation (Figure 6.2). Compared to the WT protease, the MDR protease 
variants were interfered at lower levels by the presence of regular peptides indicating the 
impaired ability of the MDR HIV-1 protease to form a complex with the substrates. All 
five HIV-1 protease variants had higher probability of forming complexes with the CA/p2 
P1’F peptide. The presence of CA/p2 P1’F significantly slowed down the processing of 
the FRET substrate. Especially, the NL4-3 and MDR 769 were completely occupied by 
CA/p2 P1’F, and the fluorescent signal maintained as the base line of background signal. 
The MDR 807, MDR 1385, and MDR 3761 had higher residual velocities of FRET 
substrate processing with the interference of CA/p2 P1’F, suggesting the decreased 
probability of complex formation. The MDR 807, MDR 1385, and MDR 3761 exhibited a 
lower probability of forming complex with the substrate p2/NC compared to the WT 
protease and MDR 769. All four MDR protease variants were unfavorable to form 
complex with the RT/RH and RH/IN.  
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Figure 6.2 Förster resonance energy transfer substrate processing ratio. The bar chart 
represents the ratio of the average FRET substrate cleavage velocity in the presence of the 
regular peptide substrate over the average FRET substrate cleavage velocity in the 
absence of the regular peptide substrate. When the velocity ratio is one, the regular 
peptide does not affect the FRET substrate cleavage by the protease. When the velocity 
ratio is zero, the FRET substrate is completely competed out by the regular peptide. 
6.2.3 The MDR protease-substrate co-crystal structures were insufficient to explain 
the different substrate binding behaviors between the MDR and WT HIV-1 
proteases 
 Based on substrate competition experiments, the substrates of interest were selected 
to co-crystallize with the MDR HIV-1 protease variant. The peptides CA/p2 P1’F and 
p2/NC were successfully crystallized with MDR 769 82T in P212121 space group. The 
CA/p2 P1’F-MDR 769 82T and p2/NC-MDR 769 82T co-crystals diffracted to 2.10 Å 
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and 2.30 Å, respectively (Table 6.4). By superposing the MDR-substrate complex 
structures on corresponding WT protease-substrate complexes, the substrate backbones 
were overlapped in both the MDR and WT complexes, and only minor conformational 
differences were noticeable in the long flexible side chains (Figure 6.3 A, B). The P1’ 
group of p2/NC in complex with MDR 769 was the major conformational deviation as 
compared to that of the WT complex. The results suggested that the static structures of 
binding conformation are insufficient to explain the difference in substrate recognition of 
HIV-1 protease variants. Dynamic simulations are required to identify the sophisticated 
differences in substrate binding among HIV-1 protease variants.  
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Table 6.4 Crystallographic statistics 
Dataset The MDR 769 82T in 
complex of substrate 
CA/p2 
The MDR 769 82T in 
complex of substrate 
p2/NC 
Data collection   
Space group P212121 P212121 
Wavelength (Å) 0.979 0.979 
Cell constants (Å) a=28.76 b=65.38 
c=92.80 
a=28.62 b=63.85 
c=91.11 
Resolution range (Å) 30.00-2.10(2.14-2.10) 30.00-2.30 (2.38-2.30) 
Number of unique reflections 10882 (507) 7945 (787) 
Completeness (%) 99.9 (99.0) 98.8 (99.5) 
Redundancy  7.6 (6.0) 4.0 (4.0) 
Mean I/σ (I) 13.2 (3.4) 10.0 (2.4) 
Rmerge a 0.162 (0.520) 0.114 (0.451) 
Refinement   
Rwork (%)b 17.29 20.00 
Rfree (%)b 23.99 27.86 
Number of atoms   
          Ligand 60 56 
          Protease 1529 1529 
          Solvent 258 137 
Average isotropic B factor (Å2)   
          Ligand 20.28 35.32 
          Protease 16.83 30.46 
          Solvent 32.62 45.32 
RMSD bond length (Å) 0.008 0.009 
RMSD bond angle (°) 1.06 1.26 
Ramachandran plot   
Allowed/generous/disallowed (%) 100/0/0 99.0/1.0/0 
aRmerge= Σhkl Σi |Ii (hkl) - <I(hkl)>| / Σhkl Σi Ii(hkl), where Ii (hkl) is the intensity of an 
observation and I(hkl) is the mean value for its unique reflection. 
bRwork =Σhkl ||Fo|−|Fc|| / Σhkl |Fo|, where Fo and Fc are the observed and calculated structure 
factor amplitudes. Rfree is calculated exactly as Rwork using a random 5% of the reflections 
omitted from refinement.  
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Figure 6.3 Substrate conformation illustrating binding to the MDR protease. (A) The 
CA/p2 P1’F binding to the MDR 769 82T (green) comparing to its binding to a WT 
protease (grey, PDB ID: 1A8K). (B) The p2/NC binding to the MDR 769 82T (green) 
comparing to its binding to a WT protease (grey, PDB ID: 1KJ7). (C) The electron 
density of CA/p2 P1’F. The mesh is an Fo-Fc OMIT map at 2.0 σ. (D) The electron 
density of p2/NC. The mesh is an Fo-Fc OMIT map at 2.0 σ. 
6.2.4 The desolvation energy required by the MDR HIV-1 protease variants to form 
protease-substrate complexes correlated with the substrate binding assay 
 Homology complex models of MDR 769, MDR 807, MDR 1385, MDR 3761, and 
NL4-3 with p2/NC or CA/p2 were built to analyze the dynamic interactions between 
substrate and protease. After 10 ns molecular dynamics simulation, the HIV-1 protease 
complex models became relatively stable (Figure 6.4, 6.5), and the movement of 
substrates was analyzed for the last 40 ps of simulation. The RMSD of each residue of 
p2/NC or CA/p2 was plotted in Figure 6.6. The lower RMSD standard deviation suggests 
B A 
D C 
P1 
P1 P1’ 
P1’ 
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a more stable substrate-protease complex. The RMSD standard deviation values of CA/p2 
binding to MDR proteases were comparable to that of CA/p2 binding to the WT HIV-1 
protease. Only the Met at P4’ site was unstable in the MDR-CA/p2 complexes. This result 
indicates that CA/p2 stabilizes MDR protease complexes and could serve as a template to 
be further developed as a resistance overcoming peptidomimetic inhibitor. The RMSD 
standard deviation values of p2/NC showed that P1 to P3 residues were stable in both the 
WT HIV-1 protease and MDR proteases while the P1’ to P3’ residues were more unstable 
in the MDR proteases compared to that in the WT HIV-1 protease. The P4 Gly, the tail of 
p2/NC, underwent large movements.  
 
Figure 6.4 RMSD values of the HIV-1 protease-p2/NC complexes. 
 
Figure 6.5 RMSD values of the HIV-1 protease-CA/p2 complexes.
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Figure 6.6 RMSD standard deviation of substrate residues in the active site of HIV-1 
protease variants. 
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 The interaction energy and desolvation energy between the substrates (p2/NC and 
CA/p2) and HIV-1 protease variants were calculated based on the molecular 
mechanics/Poisson–Boltzmann solvent-accessible surface area (MM-PBSA) method 
(121). The interaction energies of the MDR 807-p2/NC and MDR 1385-p2/NC 
complexes were stronger than those of other protease variant complexes. The stronger 
interactions were contributed by the stronger electrostatic interaction energies. The 
pattern of CA/p2 binding energies were different form that of p2/NC. The CA/p2 peptide 
bound to MDR proteases were stronger resulting in stronger electrostatic interaction 
energies.  
The electrostatic desolvation energy is an unfavorable contribution to the binding 
free energy of HIV-1 protease-substrate complexes. Compared to the electrostatic 
desolvation energy, the non-polar desolvation energy was not a large component for the 
binding of HIV-1 protease to p2/NC or CA/p2. The desolvation energy changes for MDR 
proteases in complex with CA/p2 were higher than that for the WT complex. The p2/NC 
complexes with MDR 807, MDR 1385, and MDR 3761 were calculated to have higher 
desolvation energy than MDR 769 and NL4-3 complexes. Generally, MDR proteases 
required to overcome higher desolvation barriers to bind substrates. 
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Table 6.5 Energy analysis of the HIV-1 protease-p2/NC complex 
Terms of 
binding free 
energy 
HIV-1 protease 
NL4-3 MDR 769 MDR 807 MDR 1385 MDR 3761 
∆Gintelec -103.7±11.9 -109.0±13.8 -136.5±22.1 -134.5±18.6 -82.5±11.9 
∆GintvdW -78.1±3.4 -73.4±3.8 -77.3±4.0 -69.4±3.5 -77.6±3.4 
∆Gint -181.7±11.6 -182.4±13.3 -213.9±21.5 -203.9±17.6 -160.1±12.0 
∆Gdesolvelec 176.0±8.9 184.2±9.6 203.9±17.8 223.2±17.7 261.6±9.1 
∆Gdesolvnonpolar -7.6±0.1 -7.6±0.2 -8.0±0.2 -7.4±0.2 -7.6±0.1 
∆Gdesolv 168.4±8.9 176.6±9.6 195.9±18 215.8±18 254.0±9.1 
 
Table 6.6 Energy analysis of the HIV-1 protease-CA/p2 complex 
Terms of 
binding free 
energy 
HIV-1 protease 
NL4-3 MDR 769 MDR 807 MDR 1385 MDR 3761 
∆Gintelec -158.7±27.6 -191.7±31.9 -193.8±25.1 -206.4±20.6 -169.3±18.5 
∆GintvdW -67.8±4.4 -66.6±4.4 -69.0±3.7 -59.3±4.4 -66.1±3.9 
∆Gint -226.5±25.9 -258.3±31.5 -262.8±24.6 -265.7±19.5 -235.5±17.5 
∆Gdesolvelec 281.0±24.3 282.1±24.5 313.8±14.1 298.4±18.8 332.3±16.6 
∆Gdesolvnonpolar -7.6±0.1 -8.0±0.2 -7.5±0.2 -6.8±0.1 -7.2±0.1 
∆Gdesolv 273.4±24 274.1±25 306.3±14 291.6±19 325.1±17 
 
The interaction energies (∆Gint) between the substrate and HIV-1 proteases are the 
combination of electrostatic interaction energy change (∆Gintelec) and van der Waals 
  
93 
interaction energy change (∆GintvdW). The interaction energies of the p2/NC or CA/p2 
with the MDR protease variants were not weaker compared to the interaction energy with 
the WT HIV-1 protease (Table 6.5, 6.6). Except for the interaction energy between p2/NC 
and MDR 3761, the interaction energies with all the other MDR protease variants were 
stronger than the WT protease interaction energy, which does not explain the drug 
resistance and the results of substrate competition experiments. However, the energy 
barrier of desolvation correlated well with velocity ratios in substrate competition 
experiments. The desolvation energy (∆Gdesolv) includes the non-polar desolvation energy 
(∆Gdesolvnonpolar) and the electrostatic desolvation energy (∆Gdesolvelec). The MDR proteases 
require a higher desolvation energy to remove the water shell in the active site to form 
complexes with the substrate (Table 6.5, 6.6). Pearson's correlation coefficient between 
the velocity ratios for the p2/NC peptide (Figure 6.2) and the desolvation energies of the 
p2/NC-MDR protease complexes is 0.78. Pearson's correlation coefficient for the CA/p2 
dataset is 0.81. 
6.3 Discussion 
 The study of MDR HIV-1 protease substrate preference in binding and catalysis 
improves the understanding of MDR HIV-1 protease evolution as well as the effective 
inhibition of the MDR protease variants. Novel drugs could be designed or optimized 
according to the favorable binding of substrates to the MDR HIV-1 protease. 
The identification of the substrate sub-site preference of MDR HIV-1 proteases helps 
in the design of drugs that specifically inhibit MDR HIV-1 proteases. The MDR HIV-1 
protease inhibitors may benefit patients who fail the regular protease inhibitor-containing 
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antiretroviral therapy. According to the movement of p2/NC residues as measured by 
RMSD in the protease active site (Figure 6.6), the P1’ Met is not favorable in MDR 769 
and MDR 807, and P2’ Gln is not favorable in MDR 769 either. The active site blocking 
behavior of CA/p2 and its interaction energy with MDR proteases suggests that the 
CA/p2 peptide easily forms a strong complex with HIV-1 proteases. The tighter CA/p2 
binding to the MDR protease variants as well as the reduced movement of CA/p2 in the 
MDR protease active site also supports the idea that the MDR HIV-1 protease-specific 
inhibitors against a panel of MDR HIV-1 protease variants could be developed using the 
CA/p2 as an initial template for drug-optimization.   
During the viral maturation, the processing of Gag and Gag-pol polyprotein is an 
ordered process (122). The WT HIV-1 protease should maintain varying binding affinities 
to the different substrates. However, in the substrate interference assays, the FRET 
substrate cleavage interference pattern of the WT HIV-1 protease is not preserved in the 
assays of MDR proteases. MDR proteases acquire drug-resistance by decreasing the 
probability of binding to inhibitors. It is also possible for the mutations and polymorphic 
substitutions to decrease the ability of MDR HIV-1 protease to bind substrates. The 
change in regulated substrate site processing could be a mechanism to compensate for the 
loss of viral fitness and could be a mechanism to enlarge the MDR HIV-1 variant 
quasispecies populations in an infected individual. However, the short substrate peptides 
used in this study may not reflect the processing order of the polyproteins cleavage sites 
because the structural context and protease accessibility were not evaluated.   
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 The desolvation energy is an important component for substrate and inhibitor 
recognition. The higher unfavorable desolvation energies of CA/p2-MDR complexes 
explain the resistance to the uncleavable CA/p2 reduced peptide. In the dynamic process 
of ligand binding, desolvation energy plays an important role in the ligand entry and 
protease-ligand complex formation. The MDR proteases required a higher energy to 
desolvate the substrate and the protease active site. The higher desolvation barrier for 
MDR proteases increases the difficulty of protease-ligand complex formation. The input 
structures for simulation were modeled based on the closed form MDR 769. Both the 
crystal structure and direct measurement using pulsed double electron-electron resonance 
(DEER) have confirmed a larger distance between the flaps of MDR 769 as compared to 
the wild-type protease structure (110, 123). The wide-open conformation of the MDR 
protease in the solution exposes more active site regions to solvent which may further 
elevate the desolvation barrier. Since the calculation of interaction energy and desolvation 
energy were performed using different methods, it is not appropriate to compare directly 
between the two datasets. However, the trends of energy difference among HIV-1 
protease complexes are good indicators for interpretation. 
 In conclusion, the difficulty in protease-ligand complex formation is increased for 
MDR protease due to the high desolvation energy barrier. Drug design purely based on 
the enzyme of inhibited state may not be able to reproduce the dynamic interactions 
during the formation of enzyme-inhibitor complex. The results in this chapter suggest that 
the desolvation of the HIV-1 protease active site is an important step in protease-ligand 
complex formation as well as drug resistance. Since it is computationally costly to 
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simulate the process of inhibitor-enzyme recognition, desolvation energy could serve as a 
simplified parameter to be considered in drug design. The evaluation of desolvation 
energy could be utilized as one standard to screen drug candidates. 
6.4 Author’s contribution 
The author conducted the protein expression of the inactive MDR 768 82T, active 
MDR 769, active MDR 807, active MDR 1385, and active MDR 3761 HIV-1 proteases. 
The crystallization screening, crystallization setups, structure solution, enzyme inhibition 
assays, substrate competition assays, molecular dynamics simulations, and the analysis of 
the results were performed by the author. The crystal diffraction data collection and initial 
data processing were done by Dr. Joseph S. Brunzelle from the Department of Molecular 
Pharmacology and Biological Chemistry, Feinberg School of Medicine, Northwestern 
University, Chicago, IL. 
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CHAPTER 7 STUDY OF TELAPREVIR POTENCY 
AGAINST NON-GENOTYPE 1 HEPATITIS C VIRUS 
PROTEASES 
 
7.1 Introduction 
Hepatitis C Virus (HCV) infection is more prevalent than HIV infection; HCV has 
infected approximately 170 million people worldwide (124). About 60%~80% of the 
persons infected with HCV have a chronic infection (125). To eliminate the HCV caused 
public health burden, effective treatments are needed. The classic hepatitis C viral therapy 
involves a combination drug cocktail; pegylated interferon-α-2a or pegylated 
interferon-α-2b is paired with ribavirin in a 24-to-48 week regimen. The length of the 
treatment is contingent upon the nature of viral genotype. The prospects of treatment for 
hepatitis C have improved recently, particularly with the advent of such drugs as Merck & 
Co., Inc.’s boceprevir (FDA approved on May 13, 2011) and Vertex Pharmaceuticals’ 
telaprevir (FDA approved on May 23, 2011). Both telaprevir and boceprevir are potent 
HCV protease inhibitors. The HCV serine protease NS3-4A is a heterodimer comprised of 
two HCV-encoded proteins, the catalytic subunit NS3 and the activation subunit NS4A. 
Furthermore, the HCV NS3/4A protease employs a serine protease hydrolytic mechanism. 
Zinc ions are instrumental in maintaining the structural integrity of the NS3, although 
they do not play a catalytic role as they are situated at a distance from the active site. 
Serine protease function is quite varied, but all enzymes employ a catalytic, active site 
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serine residue that plays a central role in cleaving the substrate of choice. HCV protease 
cleaves at four major junctions on the viral polyprotein precursor, which include the 
NS4A/NS4B, NS4B/NS5A, NS5A/NS5B linkages, and a self-cleavage at NS3/NS4A. 
The HCV serine protease NS3/4A is broadly considered to be among the most attractive 
targets for anti-viral, oral drugs. Telaprevir inhibits HCV serine protease via covalent 
bonding to the serine hydroxyl oxygen. Since telaprevir was developed based on 
genotype 1 HCV protease, its efficacy with the other genotypes of HCV proteases is not 
fully understood.   
The focus of this study is to illustrate a comparison of drug resistance, among 
different HCV genotypes, via molecular modeling and dynamics. Data gleaned from the 
simulation can expand the present knowledge base surrounding the virus treatment by 
providing new insight into yet untested interactions between these new inhibitors and 
various HCV genotypes. Telaprevir was initially modeled with the HCV serine protease 
NS3/4A of several different genotypes and subsequently subjected to molecular dynamics 
that simulated the interaction between protease and inhibitor. The molecular dynamics 
simulation allows a glimpse into the movement and interactions of the HCV 
protease-telaprevir complex over time.  
7.2 Results 
7.2.1 HCV NS3/4A protease expression and crystallization screening 
The constructs for HCV genotype 4a, 5a, and 6a proteases were designed for NS3/4A 
fusion proteases. The sequences of the NS3 protease domain and the NS4A peptide for 
each HCV genotypes were selected based on the closest similarity to the consensus 
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sequence of a particular HCV genotype. The representative sequences for genotype 4a, 5a, 
and 6a HCV NS3/4 proteases were determined and listed in Table 7.1. 
The HCV NS3/4A protease from genotype 4a and 6a were made by AnaSpec, Inc. 
(Fremont, CA). The expression of HCV genotype 5a protease was unsuccessful due to 
low solubility. The HCV genotype 4a protease, whose concentration is higher compared 
to that of HCV genotype 6a protease, was sent to Hauptman Woodward Institute (Buffalo, 
NY) for a high-throughput crystal-growth screening. However, no crystallization hits 
were obtained from the screening results. Moreover, no crystal grew in the grid screening 
of previously published crystallization conditions of HCV genotype 1b NS3/4A protease. 
 
  
1
0
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Table 7.1 Representative NS3/4A fusion protease sequences for HCV genotypes 4a, 5a, and 6a 
Genotype Strain Accession NS3/4 fusion protease Seq.* 
4a 01-09 DQ418782 MGSSHHHHHHSSGLVPRGSHMGSVVIVGRVVLSGSGSITAYAQQTRGLFSTIITSLTGRDTNENCG
EVQVLSTATQSFLGTAVNGVMWTVYHGAGSKTISGPKGPVNQMYTNVDQDLVGWPAPPGVKSLTP
CTCGASDLYLVTRHADVVPVRRRGDTRGALLSPRPISTLKGSSGGPLLCPMGHAAGLFRAAVCTRG
VAKAVDFVPVESLETTMRS 
5a EUH1480 Y13184 MGSSHHHHHHSSGLVPRGSHMGSVAIVGRIILSGSGSITAYAQQTRGVLGAIVLSLTGRDKNEAEG
EVQFLSTATQTFLGICINGVMWTLFHGAGSKTLAGPKGPVVQMYTNVDKDLVGWPSPPGKGSLTRC
TCGSADLYLVTRHADVIPARRRGDTRASLLSPRPISYLKGSSGGPIMCPSGHVVGVFRAAVCTRGVA
KALEFVPVENLETTMRS 
6a 6a67 DQ480520 MGSSHHHHHHSSGLVPRGSHMGCVVICGRITLTGSGSITAYAQQTRGLVGTIVTSLTGRDKNEVEG
EVQVVSTATQSFLATSINGVMWTVYHGAGSKTLAGPKGPVCQMYTNVDKDLVGWPSPPGARSLTP
CTCGSSDLYLVTREADVIPARRRGDNRAALLSPRPISTLKGSSGGPIMCPSGHVVGLFRAAVCTRGVA
KSLDFIPVENMETTMRS 
*The N terminal sequence in bold is the His tag and thrombin cleavage site from the pET28 vector.
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7.2.2 The telaprevir derivative retained sufficient potency to inhibit genotype 4 and 
6 HCV NS3/4A proteases 
Enzyme IC50 of HCV proteases from genotypes 2 and 3 were measured by Dr. 
Ladislau C. Kovari, during his sabbatical with Vertex Pharmaceuticals. Enzyme assays 
showed the potency of telaprevir against HCV NS3/4A protease of genotype 2 was 
similar to that of telaprevir against HCV genotype 1 proteases, but telaprevir exhibited 
up to 10-fold less activity against genotype 3 proteases (Figure 7.1). 
 
Figure 7.1 Genotype 1, 2, or 3 HCV protease sensitivities to telaprevir. 
To further investigate the potency of telaprevir in the treatment of HCV other than 
genotype 1, FRET substrate cleavage assays were performed to measure the IC50 against 
genotype 4 and 6 HCV proteases. The treatment efficacy of inhibitor against HCV 
genotypes from 4 and 6 can be inferred from the in vitro enzyme assays. Vertex 
Pharmaceuticals kindly provided us a second generation inhibitor based on telaprevir 
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named PI-1 (Figure 7.2). Inhibitor PI-1 is a specific, competitive, reversible, 
peptidomimetic inhibitor of HCV NS3/4A protease, which is structurally similar to 
telaprevir. PI-1 also shares the inhibition mechanism. The α-ketoamide of PI-1 forms a 
reversible covalent bond with the catalytic serine in the active site. The inhibitory 
efficacy of PI-1 against NS3/4A proteases of HCV genotype 1a, 4a, and 6a was tested. 
The IC50 of PI-1 against genotype 1 HCV NS3/4A protease was determined as 5.54 nM. 
Decreased inhibitory efficacy of PI-1 against genotype 4 and 6 HCV proteases was 
observed. The IC50 values of PI-1 against genotype 4 and 6 HCV protease were 7.19 nM 
and 13.9 nM, respectively (Figure 7.3). The inhibitory efficacy of PI-1 against genotype 
4 HCV protease is comparable to that against genotype 1 HCV protease. The decreased 
potency of PI-1 against genotype 6 HCV protease is only approximately 2-fold. 
     
PI-1         α-ketoamides 
Figure 7.2 Chemical structure of the telaprevir analog, PI-1. 
N
H
O
O
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Figure 7.3 Inhibitor PI-1 IC50 against Genotype 1, 4, and 6 HCV proteases. The IC50 
values were calculated using the SoftMax Pro Software V.5 (Molecular Devices Inc., 
Sunnyvale, CA). The IC50 values are indicated adjacent to the curves. The top panel is 
the compound inhibition experiment of the WT HIV-1 protease while the bottom panel 
is the compound inhibition experiment of the MDR HIV-1 protease. The curve data 
points presented in this figure are average numbers of triplicate readings. The Y-axis 
represents the Relative Fluorescence Units (RFU) per second. The X-axis is the 
compound concentrations in nanomolar values. The empty square symbol represents the 
Genotype 1 
IC50=5.54 nM 
Genotype 4 
IC50=7.19 nM 
Genotype 6 
IC50=13.9 nM 
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genotype 1 HCV protease activity curve while the solid square symbol and solid triangle 
symbol represent the genotype 4 and 6 HCV protease activity curve, respectively. The 
IC50 calculations were performed by fitting a four-parameter sigmoidal curve to the data 
points. To calculate the IC50 value, we used the equation y = (A-D)/[1+(x/C)^B]+D, 
where A and D are the Y-values corresponding to the asymptote at the lowest and 
highest concentration, respectively; B is a coefficient describing the slope of the curve 
(Hill coefficient); and C is the IC50 value.   
7.2.3 Telaprevir exhibits less movement when it binds to HCV genotype 1 and 
genotype 4a proteases   
 The HCV NS3/4A protease of genotypes 4a, 5a, and 6a were modeled and 
simulated for 10 ns. Using the same methodology, the HCV genotype 1b NS3/4A 
protease was simulated as a control. After a 10-ns simulation, the interaction of 
telaprevir with the catalytic triad of HCV genotype 1 NS3/4A protease was illustrated in 
Figure 7.4. The telaprevir is covalently attached to the Ser 139 hydroxyl group and 
forms a hydrogen bond with His 57.  
 
  
105 
 
Figure 7.4 Interaction of telaprevir with the catalytic triad of HCV genotype 1 
NS3/4A protease. The catalytic triad, His 57, Asp 81, and Ser 139 are shown in stick 
model. Telaprevir is represented in a green stick model. The orange cartoon model is the 
NS3 protease domain and the yellow cartoon model is the cofactor NS4A.   
 
Based on the RMSD values throughout the simulation process (Figure 7.5), the 
HCV proteases of genotypes 1b and 6a had the least amount of movement from the 
initial models while overall RMSD values of the HCV genotype 4a and 5a proteases 
were 0.2 Å larger. The RMSD values of protease-inhibitor complexes suggested the 
structural similarity between genotypes 1b and 6a proteases is greater than that between 
genotype 1b protease and genotype 4a or 5a protease. Regarding the movement of 
telaprevir (Figure 7.6), the RMSD values of telaprevir binding to HCV genotype 4a 
proteases were larger than those of telaprevir binding to genotype 1, 5, or 6 HCV 
Ser 139  
His 57  
Asp 81  
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proteases. 
 
Figure 7.5 RMSD values of HCV NS3/4A protease-telaprevir complexes during the 
10-ns simulation. 
 
Figure 7.6 RMSD values of telaprevir binding to various HCV NS3/4A proteases 
during the 10-ns simulation. 
Telapravir displayed the most relative stability when complexed with NS3/4A 
protease genotypes 1 and 4 than with genotypes 5 and 6. This conclusion is supported by 
considering the standard deviation of average RMSD taken from the final 200 frames of 
the protease-ligand complex trajectory files (final 0.4 ns of the 10-ns simulation, Figure 
7.7). A relatively lower standard deviation between plotted points (frames) of the 
molecular dynamic corresponds to a relatively greater measure of protease-ligand 
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complex stability. 
 
Figure 7.7 Standard deviation of the telaprevir average RMSD during the last 
400-ps of the simulation. 
7.2.4 The binding between telaprevir and HCV NS3/4A genotype 1 protease 
residues is superior to telaprevir complexes with the proteases of HCV genotypes 4, 
5, and 6 
Analysis of protease-ligand interactions is a direct way to evaluate ligand binding. 
The Ligplot software (81) was used to formulate and visually represent the interactions 
between the residues of a given NS3/4A protease genotype and the associated ligand, 
telaprevir. The interaction maps of telaprevir with four different genotypes of HCV 
proteases are represented in Figure 7.8. The genotype 1 protease-ligand complex 
displayed the most favorable bonding profile, showing eight hydrogen bonds compared 
with seven in both the genotype 5 and genotype 6 complexes and six in the genotype 4 
complex. These data suggest that active site binding between telaprevir and the 
implicated NS3/4A genotype 1 protease residues is superior to telaprevir complexes with 
the remaining studied genotypes (4, 5 and 6).
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Figure 7.8 Ligplot analysis of telaprevir with the proteases from various HCV 
genotypes. Hydrogen bonds appear in dashed, green line and hydrophobic interactions 
are depicted with red, pronged semicircles. 
Genotype 5a  Genotype 6a  
Genotype 4a  Genotype 1b  
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Table 7.2 Analysis results using the Protein Interfaces, Surfaces and Assemblies 
server 
Telaprevir complexes with 
HCV NS3/4A proteases 
Buried area 
(Å2) 
∆Gint 
(kcal/mol) 
Number of hydrogen 
bonds with inhibitor 
Genotype 1 475.9 -2.18 8 
Genotype 4 492.6 -1.62 6 
Genotype 5 480.2 -0.87 7 
Genotype 6 475.5 -0.76 7 
When genotype 1 NS3/4A protease-telaprevir complex is compared with telaprevir 
binding to genotype 4, 5, and 6 proteases, the genotype 4 NS3/4A protease had fewer 
hydrogen bonds with the ligand telaprevir, but more van der Waals interactions relative 
to the other genotypes. The genotype 4 protease complex displayed one fewer hydrogen 
bonding residue than do genotypes 1, 5 and 6 HCV proteases (Table 7.2). The genotype 
4 protease complex lacked a hydrogen bond between Cys 159 and the inhibitor, whereas 
genotypes 1, 5 and 6 all displayed a hydrogen bond between the Cys 159 residue and 
telaprevir. The HCV protease-telaprevir interactions were further analyzed using PDBe 
PISA server (126). In the PISA analysis, the covalent bond between the HCV protease 
and telaprevir was manually removed. Telaprevir binding to the genotype 4 HCV 
protease had the largest buried ligand area. In the Table 7.2, ∆Gint indicates the solvation 
free energy gain upon complex formation, which suggested that the genotype 1 HCV 
protease-telaprevir is the tightest complex among the genotype 1, 4, 5, and 6 complexes. 
According to buried ligand area and ligand RMSD deviation results, the genotype 4 
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HCV protease-telaprevir RMSD data suggest that telaprevir shows comparable binding 
of between the 1 and 4 genotypes. 
Table 7.3 Interaction energy between telaprevir and HCV proteases 
Telaprevir complexes 
with HCV NS3/4A 
proteases 
Electrostatic 
interaction energy 
(kcal/mol) 
Van der Waals 
interaction energy 
(kcal/mol) 
Nonbonded 
interaction energy 
(kcal/mol) 
Genotype 1 -87.89 -55.12 -143.01 
Genotype 4 -77.62 -56.88 -134.50 
Genotype 5 -78.21 -55.78 -134.00 
Genotype 6 -81.18 -55.69 -136.87 
 The interaction energy calculation of the HCV protease-telaprevir complexes 
supported the results of PISA analysis. Genotype 1 HCV protease-telaprevir complex 
showed the strongest total interaction energy (-143.01 kcal/mol, Table 7.3). The 
Genotype 4 HCV protease-telaprevir complex was stronger in van der Waals interactions 
but weaker in electrostatic interactions, which is correlated with the larger ligand buried 
area and loss of one hydrogen bond in Table 7.2. In summary, based on the energy 
calculations, telaprevir inhibited genotype 1 HCV protease with the best potency but 
retained sufficient potency to effectively inhibit non-genotype 1 HCV proteases. 
7.3 Discussion 
The development of telaprevir greatly benefits the hepatitis C patients. Since 
telaprevir has only been approved for the treatment of patients infected with genotype 1 
HCV, more basic researches need to be conducted prior to the initiation of clinical 
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studies to investigate the potency of telaprevir against non-genotype 1 HCV strains. The 
first section of this study is the testing of in vitro inhibitory efficacy of the telaprevir 
analog against genotype 4 and 6 HCV proteases. The second section of the study is the 
determination of the structures of genotypes 4, 5, and 6 HCV proteases in complex with 
telaprevir using homology modeling and molecular dynamics.  
According to the enzyme assays with the telaprevir analog, PI-1, and simulation 
results of the HCV protease-telaprevir complex, the binding patterns of telaprevir to 
genotype 4, 5, and 6 HCV proteases are conserved. A preliminary conclusion is that 
telaprevir possesses sufficient potency to treat genotype 4, 5, and 6 HCV strains. 
Therefore, it is possible to expand the patient target population of telaprevir or its 
derivatives to those infected with non-genotype 1 HCV variants. A weakness for the 
enzyme assays is that the second generation inhibitor, a telaprevir derivative, was used 
rather than original telaprevir. The potency of the telaprevir derivative in clinical tests is 
unclear. 
The structural study of telaprevir binding to NS3/4A proteases of different 
genotypes may lead to the developing treatments for patients infected with non-genotype 
1 HCV. To improve telaprevir efficacy with the other HCV genotypes, one strategy 
might be to structurally modify telaprevir to restore the protease binding network, such 
as the loss of hydrogen bond with the protease residue Cys 159. Another strategy is to 
extend the flexible end (the P4 and P5 groups) of telaprevir to make stable contacts with 
the HCV protease, which reduces the binding instability of the inhibitor. 
The telaprevir binding to HCV NS3/4A protease is a two-step process. Telaprevir 
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first forms a weaker non-covalent collision complex with the HCV protease, and then a 
covalent bond is formed between telaprevir and the catalytic serine of the HCV protease. 
In this simulation study, the HCV protease-telaprevir complexes are modeled as the 
covalently attached complex. Whether telaprevir is able to successfully form the 
non-covalent collision complex with non-genotype 1 HCV proteases has not been 
examined. In future experiments, the ligand binding affinity of non-covalent HCV 
protease-telaprevir complexes will be studied to further explore the potential of 
telaprevir in the treatment of patients with non-genotype 1 HCV.   
7.4 Author’s contribution 
The author performed the enzyme assays and set up the molecular dynamics 
simulations. The HCV protease expression experiments were carried out by the 
scientists at AnaSpec, Inc. (Fremont, CA, USA). The author and his lab member, Samuel 
J. Reiter, analyzed the data. Samuel J. Reiter produced the figures of the RMSD plot. 
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CHAPTER 8 FUTURE DIRECTIONS 
 
Drug discovery is still a trial-and-error testing process. Rational design and in silico 
evaluation may accelerate this process. We will propose new modifications of lopinavir 
and evaluate them by simulating the inhibitor-protease interactions. The promising 
candidate molecules will be synthesized through collaboration with medicinal chemists. 
The goal is to develop inhibitors that target with equal potency both the WT HIV-1 
protease and the MDR HIV-1 protease. 
The drug resistance is caused by multiple steps of dynamic interactions. Crystal 
structures plus molecular dynamics are powerful tools to understand the complicated 
mechanisms. In the Protein Data Bank, there are still a limited number of apo HIV-1 
protease structures. Increasing the diversity of the apo HIV-1 protease structures and the 
HIV-1 protease receptor structures for a given protease inhibitor will improve our 
knowledge of protease flexibility upon drug binding. Furthermore, we will simulate the 
movement of the protease flaps that is triggered by inhibitors, possibly linking protein 
flexibility with drug resistance.  
Regarding the HCV project, we will study the drug resistant of HCV protease 
mutations to boceprevir, another newly approved HCV protease inhibitor. Boceprevir 
inhibits the HCV protease catalytic serine through the α-ketoamide function group as 
described earlier for telaprevir. During the clinical trial, several mutations that cause 
boceprevir resistance have been identified. The goal is to crystallize the boceprevir 
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resistant HCV NS3/4A protease mutants with or without boceprevir as starting models 
for molecular dynamic simulations.   
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The antiviral drug development has improved steadily to treat the infections of 
human immunodeficiency virus (HIV) and hepatitis C virus (HCV) which represent 
heavy public health burdens. The viral protease plays an indispensable role in viral 
maturation and therefore becomes one of the most important targets for drug design. 
Nine HIV-1 protease inhibitors and two HCV protease inhibitors have been developed 
and approved by the U.S. Food and Drug Administration. However, mutations in the 
protease decrease reduce the efficacy the drugs. In this study, the enzyme assays indicate 
that darunavir and tipranavir exhibit the most potent inhibition against the multi-drug 
resistant (MDR) HIV-1 protease, which is supported by the co-crystal structures of the 
MDR protease-darunavir complex and the MDR protease-tipranavir complex. The MDR 
HIV-1 protease not only decreases the susceptibility to drugs but also impedes the 
formation of protease-substrate complex. Molecular dynamics simulation results show 
that the MDR HIV-1 protease needs to conquer a higher desolvation energy barrier to 
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bind the substrate. Besides the study of drug resistance mechanisms, two drug discovery 
methods have been carried out in the study. One method is the modification of a current 
drug, lopinavir. The potency of the lopinavir analog against the MDR HIV-1 protease 
increases. The other method is the identification of a novel HIV-1 protease inhibitor 
scaffold to increase the structural diversity of inhibitors. In the HCV section, the study 
focuses on an HCV NS3/4A protease inhibitor, telaprevir, which is approved for the 
treatment of patients infected with the HCV genotype 1. The enzyme assays and 
molecular dynamic studies suggest that telaprevir may retain sufficient potency to treat 
the non-genotype 1 HCV strains. 
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